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STELLINGEN 
DB werking van de tumor-promotor dieldrin berust op een 
irreversibele versnelling van de oncogenese in de levers van 
CF-1 muizen. 
dit proefschrift 
Dieldrin veroorzaakt een discrepantie tussen de chronologische 
en biologische leeftijd van de lever; de grote gelijkenis 
tussen de tijdverschuiving bij de tumor-vorming en de poly-
ploidisering duidt op een oorzakelijk verband tussen beide 
fenomenen. 
dit proefschrift 
De bepaling van de hepatocellulaire polyploidiseringsgraad in 
muizen biedt goede perspectieven voor de ontwikkeling van een 
toets voor de screening van stoffen op levertumor promoverende 
eigenschappen. 
dit proefschrift 
4. De polyploidisering van hepatocyten ten gevolge van dieldrin 
behandeling komt voornamelijk tot stand door DNA synthese en 
veel minder door kernfusie. 
dit proefschrift 
5. Tumor-promotoren zijn niet in staat in cellen of organen 
nieuwe karakteristieken te introduceren; hun werking berust 
op de beinvloeding van bestaande fysiologische mechanismen. 
6. Apoptosis (controlled death) van cellen in lever foci na be-
eindeging van de behandeling met tumor-promotoren (Bursch et 
al.) kan, gezien de irreversibele effecten van zowel dieldrin 
(dit proefschrift) als phénobarbital (Peraino et al.) op de 
levertumor ontwikkeling, het ogenschijnlijk verdwijnen van 
deze foei niet verklaren. 
U. Bursch, B. Lauer, I. Timmermann-Trosiener, G. Barthel, 
3. Schuppler and R. Schulte-Hermann. Carcinogenesis 5 
(1984) 453-458. 
C. Peraino, R.J.H. Fry, and E. Staffeid. Cancer Res. 37 
(1977) 3623-3627. 
7. Bij het onderzoek naar de mutagene uerking van een stof dient 
de S9 mix bij voorkeur te worden bereid uit een met dezelfde 
stof geinduceerde lever. 
8. De conclusie van Silber et al. dat de genen voor L- en K-
pyruvate kinase isoenzymen niet gelijktijdig actief zijn omdat 
er geen L-K hybride van dit enzym in hepatocyten voorkomt is 
voorbarig. 
0. Silber, E. Checinska, 3, Rabczynski, A.A. Kasprzak and 
1*1. Kochman. Europ. 3. Cancer 14 (1978) 729-739. 
9. De door de EG vastgelegde maximaal toelaatbare concentratie 
voor bestrijdingsmiddelen in drinkuater (0.0001 mg/l) houdt 
onvoldoende rekening met de toxicologische heterogeniteit 
van deze stoffen. 
10. Het bestaan van een of meerdere z.g. Super Attractor(s) 
(Dressler et al.) zou zouel de beueging van de melkueg t.o.v. 
de achtergrond straling als ook het theoretische tekort aan 
(uaargenome) massa in het heelal kunnen verklaren. 
A. Dressier, S.M. Faber, D. Burnstein, R.L. Davies, 
D. Lynden-Bell, R.3. Terlevich, and G. Uegner. Astro-
physical 3. 313 (1987) 37-42. 
11. Bij de bepaling van de "acceptable daily intake" voor lichaams-
vreemde stoffen (1/100 van de "no observed effect level") uordt 
onvoldoende rekening gehouden met mogelijke synergetische 
effecten van de steeds groter uordende aantallen lichaamsvreemde 
stoffen; hierdoor kunnen risico s voor de gezondheid onderschat 
uorden. 
12. Astrologie oefent op vele mensen dezelfde facinerende uerking 
uit als "roddelbladen" en heeft inhoudelijk dezelfde uaarde. 
Ben van Ravenzuaay 
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I N T R O D U C T I O N 
1. INTRODUCTION 
1.1 General Introduction and Objectives of the Study 
Some features that make cancer cells different from normal cells are: 
1) Cancer cells grow and divide with less restraint than normal cells in 
which division is closely regulated. 
2) Cancer cells are, more or less, dedifferentiated and therefore do not 
perform all of their normal functions. 
3) Cancer cells are immortalized and therefore do not die on schedule. 
The result of these cellular characteristics is an overgrowth (tumour) of 
misfunctioning cells that interferes with the activities of normal cells 
and tissues. 
The eukaryotic cell cycle (Fig. 1) can be divided into 4 phases: 
- Gl, as the period between mitosis and the beginning of DNA syntheses, 
- S, the period of DNA synthesis, 
- G2, the premitotic interval, 
- M, the period of mitosis. 
Pntmg phjj* 
Fig. 1. Eukaryotic cell cycle. 
10 
S, G2 and M periods are relatively constant in most cells (Pardee, 1978) 
whereas the length of the Gl phase can vary considerably in different cells 
(Gross, 1968). It was thus hypothesized that tumour growth would result 
from a shortened G2 phase. However, it was observed that the cell cycle of 
cancer cells is, generally, not shorter than that of normal cells (Braun, 
1974), contradicting the aforementioned theory. Since cellular division in 
cancer cells is not faster than in normal cells, tumour growth could occur 
when cells divide without needing to do so. In adult animals, cells divide 
only to replace other cells which were lost, in this way a tight balance 
between cell loss and gain is maintained. Tumour growth thus takes place 
because cancer cells divide, although there is no need for such a division. 
Many studies have clearly demonstrated that numerous cellular consti-
tuents normally present during embryonic or fetal life, but absent in 
tissues or organs of mature individuals, reappear in neoplastic tissues. 
Among the common features of embryonic and neoplastic cells are: a-feto-
protein (Abelev, 1963), carcinoembryonic antigen (Fischman, 1976) and 
several isoenzymes, such as pyruvate kinase-K (Weinhouse, 1972), lactic 
dehydrogenase-M4 (Fischer, 1983) and aldolase-A (Schapera, 1973). The loss 
of tissue specific functions, with a concomitant re-expression of fetal 
gene products, has been found to be more pronounced in tumours which are 
more malignant (Wilis, 1967). Apparently, an inverse relationship exists 
between differentiation and cellular division (Fig. 2). 
The fetal characteristics of cancer cells have initiated many investi-
gations concerning the role of stem cells, i.e. cells which have retainted 
their proliferative capacities and which are not fully differentiated, in 
carcinogenesis. 
11 
STEM CELL 
Ä 
<= 
MITOTIC RATE 
RESPIRATION 
MATURE 
CELL 
Fig. 2. Characteristics influenced by the state of cell maturati on. 
From such studies on testicular teratocarcinoma (Pierce, 1967), Pierce 
(1970) concluded that in carcinogenesis the target cell is the stem cell 
normally present in tissues. This concept therefore excludes adult or 
mature cells as possible targets for neoplastic transformation. A somewhat 
different concept, along the same line of reasoning, was developed by 
Potter (1969) and Potter et al. (1972), which was formulated as: "Oncogeny 
as blocked ontogeny". In their view, cancer would develop if stem cells (or 
other cells with proliferative capacity) are arrested in their differentia-
tional development, and are thus forced to display a higher rate of proli-
feration (see Fig. 2). This hypothesis could explain the large diversity of 
neoplasms, ranging from "minimally deviated" to highly malignant varieties. 
Both the aforementioned hypotheses infer that cancer originates from 
cells which were not fully differentiated. The question whether or not 
differentiated cells can undergo dedifferentiation and transformation re-
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suiting in cancer, has been discussed with some controversy among cancer 
biologists. There is, however, some evidence for the reversibility of diffe-
rentiation (Yamada, 1967; Burgess, 1974; Stone, 1950). Probably the best 
investigated model for the reversibility of differentiation is liver re-
generation in rodents after partial hepatectomy. Bresnick (1971) summarized 
several cellular morphological alterations after partial hepatectomy which 
were also found in fetal hepatocytes. Most of these changes were also ob-
served in preneoplastic nodules in rats treated with the carcinogen diethyl -
nitrosamine (Bruni, 1973). Furthermore, a step-wise dedifferentiation of 
enzyme activity after partial hepatectomy has been reported (Curtin, 1983), 
which resulted in a similar enzymic pattern of regenerating, fetal and neo-
plastic liver. It would thus appear that differentiation in hepatocytes is 
a reversible process, which suggests that all hepatocytes could be a target 
for carcinogenic action. In this context, Uriel (1969) has advanced the 
thesis of "unbalanced retrodifferentiation" which holds that during the 
preneoplastic phase of liver carcinogenesis, hepatocytes retrodifferentiate, 
without the compensatory differentiation thereafter (Uriel, 1975). 
The presented hypotheses "oncogeny as blocked ontogeny" and "unbalan-
ced retrodifferentation" do not address the question as to whether a change 
in the genetic information (mutation) is involved in carcinogenesis or 
whether persistent alterations in the expression of the genetic information 
already present (i.e. an epigenetic mechanism) are sufficient to result in 
a neoplasia. Many investigators have proven beyond doubt the importance of 
mutagenic mechanisms involved in carcinogenesis. The close resemblance 
between tumour cells and fetal cells, however, suggests that changes in the 
expression of genetic information already present in the nucleus, may also 
play an important role. 
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Objectives of the Study 
Many drugs, insecticides, food additives and other chemicals are known 
to induce characteristic changes in the livers of laboratory animals. These 
changes include liver enlargement, induction of microsomal enzyme sytems 
and proliferation of the smooth endoplasmic reticulum (Goldberg, 1966; Kunz 
et al., 1966; Wright et al., 1972). These changes are not accompanied by 
evidence of liver damage and are reversible upon withdrawal and elimination 
of the compound (Goldberg, 1966; Wright et al., 1972). Consequently, these 
changes are likely to be adaptive responses of the liver to increased 
functional demands. However, prolonged exposure of various strains of mice 
to xenobiotic compounds has been shown to result in increased frequencies 
of liver tumours in these mice (Peraino et al., 1973; Walker et al., 1973, 
Ruebner et al., 1981). 
Several mechanisms have been proposed to explain the tumorigenic effects 
of microsomal enzyme inducers in mouse liver: 
1) Microsomal enzyme inducers may enhance or facilitate the expression of 
a pre-existing oncogenic factor, 
2) Microsomal enzyme inducers may be weak carcinogens themselves, and are 
only detected in susceptible species, 
3) The induction of microsomal enzyme systems could render the liver more 
susceptible to tumour formation as a result of increased capability to 
synthesise proximate or ultimate carcinogenic forms from environmental 
pre-carcinogens. 
The last possibility was extensively studied using dieldrin as a microsomal 
enzyme inducer and CF-1 mice as experimental animals (Tennekes et al., 
1981). No difference in liver tumour incidence were observed between CF-1 
mice bred, reared and maintained on a semi-synthetic diet and filter-paper 
bedding, and those exposed to a conventional diet and sawdust bedding. 
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Dieldrin was found to be equally tumorigenic in both environments. 
The dose-response characteristics for chemically induced tumour formation 
have been elucidated by Druckrey and co-workers (Chapter 2.2), who demon-
strated that carcinogens interact irreversibly with their specific recep-
tors, and that the result of this interaction is also irreversible, re-
sulting in a time-dependent reinforcement factor "n". Since no evidence 
has been found for irreversible interactions of microsomal enzyme inducers 
with cellular components, it is conceivable that enhancers of carcinoge-
nesis display different dose-response characteristics. 
The first objective of this study is to establish whether dieldrin 
should be considered as a weak carcinogen or as a tumour promotor. To dis-
criminate between these possibilities the dose-response characteristics of 
dieldrin-enhanced liver tumour formation in CF-1 mice had to be established. 
The second objective of the present study was to establish qualitative 
and quantitative links between the functional pressure, polyploidization 
and liver tumour formation in CF-1 mice, using dieldrin as a model compound. 
Previous studies (Wright et al., 1972; Tennekes et al., 1981) have shown 
that the induction of liver enlargement and of microsomal enzymes is 
strictly dose-dependent and, most importantly, time-independent. 
The enhancement of polyploidization of liver nuclei in mice exposed to 
microsomal enzyme inducers may not follow this pattern. Polyploidization in 
mice increases in the course of time (Shima and Sugahara, 1976) as well as 
with microsomal enzyme induction (Böhm and Noltemeyer, 1981; Schulte-
Hermann, 1979). Thus, like the formation of liver tumours, polyploidization 
is a dose- and time-dependent process. 
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1.2 Dose-Response Relationships in Carcinogenesis 
As the quantity of experimental results threatens to obscure the 
general view on the subject, the need arises to bring order into the seeming 
chaos. Mathematics is the only "language" that will enable us to give an 
exact representation of the subject. 
For quantitative studies on the effects of xenobiotic compounds on 
carcinogenesis, knowledge is required concerning the pharmacokinetics of 
the applied compound. 
When an (experimental) animal is exposed to a (foreign) compound, re-
sorption is the first process to influence the ultimate effect of the com-
pound. The second process is the distribution of the compound in the body 
with concomitant excretion and metabolism. Both these processes determine 
the dose which may ultimately reach the target cell (with its specific re-
ceptors). The reaction of the compound with specific cellular receptors is 
the third step, and the effect of the compound-receptor interaction is the 
fourth, and last, step which then may result in a biological reaction of 
the cell. 
Druckrey and Kupfmüller (1949) gave a theoretical explanation for 
different dose-response relationships, based on the experiments of Clarke 
(1937). According to them the biological response of the cell, when exposed 
to a concentration C at the site of interaction, depends firstly on the 
reversibility of the compound-receptor interaction and secondly on the re-
versibility of the effect of this interaction. Three different types of 
dose-response relationships can be distinguished: 
1. When the time constant TR for the reversibility of receptor binding is 
small, i.e. the compound-receptor interaction is quickly reversible, and 
the time constant T r for the reversibility of the effect is also small, 
i.e. the biological response caused by receptor binding is quickly re-
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versible, then the biological response is proportional to the compound 
concentration ("Konzentrationsgift"). Therefore, the response will be 
completely reversible after elimination of the compound. 
(Fig. 3, curve 1) 
2. When either receptor binding or the effect of receptor binding is irre-
versible, the biological response will depend on the concentration as 
well as on the duration of treatment ("c«t-Gift"). In both cases the 
response will be additive and irreversible. 
(Fig. 3, curve 2) 
3. When both receptor binding and its effect are irreversible, then a time-
associated acceleration of the biological response would take place 
("Verstärkerwirkung"). Such a dose-response relationship would imply 
that the effect of a low concentration of the compound, which may not 
produce a significant response during the initial phases of treatment, 
will be amplified in time and result in an increasing response (Table I, 
Fig. 3, curve 3 ) . 
Table I . The theoretical basis of dose-revponse 
Reversibilitv of 
receptor binding 
T R - 0 
T R - 0 
T R - o o 
T R - o o 
Receptor bindine in 
relation to compound 
concentration 
C R - C 
C R - C 
C R - 1 C dt 
C R - 1 C ut 
relationships accord 
Reversibilitv 
of the effect 
T f - 0 
T f — 
T r - 0 
T r - o o 
ne to H.Druckrey 
Effect in relation 
receptor binding 
E- C 
E - | C R dl 
E - C R 
E - | C R dl 
and K 
lo 
Küpfmüller (1949)J 
Effect in relation to 
compound concentration 
E - c 
E - 1 c dt 
E ~ | c dt 
E - l | c dt 
Dose-response characteristics 
Dose-dcpendcnl 
rKon/cntrationsgilt') 
Dose- and limc-dcpcndent 
(•C.I - G i f l l 
Dose- and timc-dcpcndenl 
( c l . - G i l l ' ) 
Dose- and time-dependent 
tinv-associaled acceleration 
C Verslarkerw irkung't 
*TR~* = time constant for the reversibility of receptor binding; Tr— ~ time constant for the reversibility of the effect: c = compound concentration; CR = 
concentration of receptor binding; E = effect. 
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Fig. 3. Time-effect relationships for the three basic compound-receptor 
interactions. 
In studies concerning the carcinogenic effects of 4-dimethylamino-
azobenzene (4-DAB) on rat liver, Druckrey (1943) and Druckrey and Kupf-
miiller (1948) reported that the dose-response characteristics of this com-
pound in the range of 10-30 mg/day can be expressed as "c-t=constant". 
This indicates that (liver) tumour formation is associated with a constant 
total tumorigenic dose. Moreover, it was concluded that this carcinogen 
acts irreversibly and cumulatively. At a treatment level of 1 mg/day, how-
ever, a remarkable deviation from the c-t=constant relation was observed. 
At this dose level (liver) tumour formation was observed after the applica-
tion of a significantly lower total tumorigenic dose, when compared with 
the 10-30 mg/day treatment levels. In other words, the tumour induction 
period was shorter than expected for a "ct=constant" relationship. In 
later studies (Druckrey, 1951; Druckrey and Schmähl, 1962) it was observed 
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that the effects of low-dose carcinogen treatment on tumour formation were 
accelerated in time (irreversibility of both receptor binding and its 
effect) and that the formulated "ct=constant" relationship was not cor-
rect. It was merely due to the extreme low reinforcement factor of 4-DAB 
that an apparent "c-t=constant" relationship was observed. In a review of 
his own work and that of others Druckrey (1962) formulated the equation: 
d-tn = constant (1) 
where d = dose of the carcinogen, t = time period to 50 % tumour incidence 
and n ( 1) = a factor expressing the acceleration of carcinogenic process 
in time (reinforcement factor). As can be seen in Table II, "n" varies 
between 1.1 and 4.7 for different carcinogens and experimental animals. 
Table II. Druckrey's "n" (reinforcement factor) for several carcinogens 
Carcinogen Animals "n" Reference 
Methylcholantrene 
4-dimethylaminoazobenzene 
3,4 benzo(a)pyrene 
3,4 benzo(a)pyrene 
1,2,5,6 dibenzanthracene 
diethyl nitrosamine 
dimethyl aminostilbene 
u.v. light ( 312 mu.) 
diethanol nitrosamine 
mice 
rats 
mice 
rats 
rats 
rats 
rats 
mice 
rats 
2.1 
1.1 
4.0 
4.7 
4.7 
2.3 
3.0 
2.0 
4.0 
Horton and Denman (1955) 
Druckrey et al. (1943, 
1948) 
Poel (1955) 
Bryan and Shimkin (1943) 
Bryan and Shimkin (1943) 
Druckrey et al. (1963a) 
Druckrey et al. (1963b) 
Blum (1959) 
Druckrey et al. (1967) 
In equation (1) a quantitative relationship between tumour formation 
and the dose level of a carcinogen is expressed. Tumour formation can be 
regarded as a process running at a certain velocity and should therefore 
be measured in units of reciprocal time. In Druckrey's words: In my re-
ports I have clearly demonstrated, theoretically as well as experimentally, 
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that the latency period can be regarded as an expression of the velocity of 
the carcinogenic process. In the equation however, this fact is not taken 
into account. Rather, log reciprocal D versus log T was chosen, because the 
resulting equation appeared to be simple and expressive. These matters 
were, 25 years ago, anyhow so novel, nearly shocking. The scientific 
correct expression would have been: 
(1/T)n = k-D (2) 
which would hardly have been understood (Tennekes, personal communication 
with Druckrey). 
The Druckrey equation not only holds for chronic exposures but was 
also found for single-dose experiments (Druckrey, 1967). 
The fact that even a single dose of a carcinogen may lead to tumour 
formation emphasizes the potency of the reinforcement factor, as predicted 
by Druckrey and Kupfmiiller (1949) in the event of irreversibility of both 
receptor binding and its effects. 
The possibility of inducing tumours with a single dose of a carcinogen 
was used by Druckrey et al. (1967, 1970) to study the sensitivity of ex-
perimental animals to carcinogens in various phases of life. Some of the 
results obtained in these experiments are summarized in Table III. 
Table III. The effects of a single dose of ethyl-nitroso-urea (20 mg/kg 
body weight) on rats of several ages 
Age Medium Tumour Tumour Yield Tumours/Rat 
(days) Induction Period (days) (%) 
1 
10 
30 
340 
360 
600 
100 
91 
62 
2.2 
1.9 
0.6 
These results clearly demonstrate the decreasing sensitivity of rats 
to ethyl-nitroso-urea (ENU) with age. In a different study (Ivankovic and 
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Druckrey, 1968) it was demonstrated that the carcinogenic effect of ENU is 
highest in embryos shortly before birth. In these experiments most tumours 
were found in the nervus trigemini, which develops its activity a few days 
before birth (suckling response) and declines with increasing age. There-
fore, it was suggested that during differentiation organs may be most 
sensitive to the effects of carcinogens. 
It is essential to pay attention to the mathematical approach for 
dose-response relationships developed by Druckrey and Kupfmiiller (1949). In 
their analysis the velocity of receptor binding (association) of a compound 
can be expressed as: 
IC-C-(RO-CR) (3) 
where k = reaction constant, C = concentration at the site of interaction, 
R0 = total number of specific receptors (free receptor concentration at 
the beginning of the experiment) and CR = number of occupied specific re-
ceptors. The velocity of dissociation can be expressed as: 
CR/TR (4) 
where TR = a time constant indicating the extent of reversibility of re-
ceptor binding. Thus, the velocity of the changes in bound-receptor concen-
tration (CR) equals: 
dCR/dt = k-C (R 0-CR) - CR/TR (5) 
Druckrey and Kupfmiiller (1949) assumed that the effect of receptor 
binding would depend upon the relative receptor binding ( C R / R 0 ) . Substi-
tution of C R / R 0 in equation (5) yields 
^ ! ° .
 k.C[l-CR/R0] - * & <6> 
dt Tr 
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With compounds that bind irreversibly to receptors no dissociation of re-
ceptor binding will occur; thus, in these cases equation (6) can be modi-
fied to: 
^ =
 k.C[l-C R/R 0] (7) 
dt 
In the case of chronic exposure to a constant concentration c of an irre-
versibly bound agent, equation (7) can be solved by integration: 
CR/R0 = 1-e K L z (8) 
Carcinogens are compounds which have been shown to bind irreversibly 
to their receptors. Moreover, the result of the receptor binding is also 
irreversible (thus, the neoplastic process is being accelerated with time). 
These findings are expressed in Druckrey's reinforcement factor "n". The 
amount of relative receptor binding, C R / R 0 , may be regarded as the propor-
tion of the oncogenic road already covered, with cancer as the ultimate 
destination (when C R / R 0 = 1). Thus C R / R 0 reflects the relative carcinogenic 
risk (P) of an exposed individual or population. Equation (8) may thus be 
rewritten as: 
P - l-e-k'C-tn (9) 
Carcinogenic risk can be calculated using the extended form of the Weibull 
model for tumour formation: 
-[a + ßdf-t r (10) 
P = 1-e 
where: P = probability of a tumour at time t, d = dose, t = obser-
vation time, m = shape parameter for dose, r = shape para-
meter for the time to a tumour, a = parameter measuring 
the background tumour probability (P0) with a = -ln(l-P0), 
ß = scale parameter. 
Equation (10) can be shown to be consistent with the Druckrey equation: 
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In Druckrey's studies the parameter a, which measures the background tumour 
probability, was virtually zero. For such a case, the Weibull equation can 
be reduced to: 
P = i-e-ßd #t (ID 
Considering a defined risk, e.g. P = 0.5, equation (11) becomes: 
0.5 = l-e"Bd ' l (12) 
which can be reduced to: 
'
1n
 °-
50 1/m
 = d-tr/m = d-tn . constant (13) 
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The extended form of the Weibull model for tumour risk has been shown to 
have an excellent fit with the experimentally observed tumour data (Carl-
borg, 1981). Thus, even without the knowledge of molecular events involved 
in carcinogenesis, Druckrey and Kupfmiiller were able to provide a theore-
tical explanation for the dose-response relationships observed in carcino-
genesis. 
1.3 THE TWO STAGE MODEL 
1.3.1 Introduction 
One of the first theories concerning carcinogenesis was the chronic 
irritation theory (reviewed by Ewing, 1940). This theory was based on the 
observations of Pott in 1775 that chimney sweeps had a high incidence of 
scrotal cancer; he attributed this to their constant contact with coal tar 
and soot. That excessive exposure to sunlight led to the development of 
skin cancer, following a longer period of solar dermatitis, was also re-
garded as further support for the chronic irritation theory. With increa-
sing experimental observations, however, this theory was seriously criti-
cized and had to be abandoned. 
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More than half a century ago it was observed that wounding or treat-
ment with chemical irritants accelerated the development of tumours in 
mouse skin, pretreated with coal tar or 3,4-benzo(a)pyrene (Deelman, 1924; 
Twort, 1939). A more pronounced cocarcinogenic effect on mouse skin was 
observed with croton oil (Berenblum, 1941), which caused a rise in tumour 
incidence from 0-6% in the groups receiving diluted benzo(a)pyrene alone 
to 37% when croton oil, or 80% when croton resin, were added. The tumour 
incidence with croton oil or croton resin alone was negligible. Thus, 
evidence was found that two distinct mechanisms were involved in carcino-
genesis. This evidence was extended by the experiments of Rous and co-
workers. Tar painting of rabbit ears was observed to result in the develop-
ment of papillomas, when treatment was discontinued, however, the papillo-
mas tended to regress. Renewed treatment after a long interval of non-
treatment produced papillomas at the exact sites where they had previously 
existed (Rous, 1941). Accordingly, the concept of a tumour existing in a 
sub-threshold state, requiring additional aid for progressive neoplasia 
was formulated. The aforementioned experiments were repeated using methyl -
cholantrene or benzo(a)pyrene as the primary stimulus, and non-carcinogenic 
stimuli (turpentine or mechanical injury) as the secondary treatment, with 
the same results (Rous, 1941; MacKenzy and Rous, 1941; Friedwald and Rous, 
1944). These results were conceptualized by postulating that "carcino-
genesis was composed of an initiating process, responsible for the conver-
sion of normal into latent (or dormant) tumour cells, and a promoting pro-
cess, whereby these latent tumour cells were made to develop into actual 
tumours" (Friedwald and Rous, 1944). The two stage model*for carcinogenesis 
was further refined by Mottram (1944), who applied the carcinogen for the 
initiating action only once. A schematic summary of the e-xperimental crite-
ria that define the two-stage model for skin carcinogenesis is given in 
Figure 4. 
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Fig. 4. Schematic summary of the experimental criteria that define skin 
tumour formation by the initiation and promotion components of the 
process of carcinogenesis. 
It should be noted, however, that the two-stage model cannot always be 
used to explain all observations in carcinogenesis. It has been demonstrated 
that plant neoplasia can be established and maintained without the necessity 
for any alteration of the genetic information (Lutz, 1971; Binns, 1973). 
Further evidence for the involvement of epigenetic mechanisms in carcino-
genesis was obtained in studies with virus-transformed frog renal cells. 
When these nuclei are transplanted into enucleated, fertilized frog eggs, 
some of these will develop into normal swimming-stage larvae, or tadpoles 
(King, 1965). Moreover, McKinnel et al. (1969) isolated triploid nuclei 
from the frog renal carcinoma, and conducted the same experiment as de-
scribed above. However, in this study normal, triploid tadpoles developed. 
The importance of these studies is the demonstration that the genetic in-
formation of a cancer nucleus is sufficient for normal development of a 
fertilized egg cell and that non-nuclear factors play a critical role in 
the expression of the neoplastic potential. 
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1.3.2 Initiation 
According to Rous' terminology, initiation may be defined as the for-
mation of "latent" tumour cells. Since initiation can be achieved with a 
single application of a carcinogen (Mottram, 1944) and the thus formed 
latent tumour cells may be forced to express their transformation by tumour 
promotor treatment long after initiation (Rous and Kidd, 1941), it was con-
cluded that initiation was an irreversible process. The fact that the neo-
plastic state is transferred from mother to daughter cells suggested that 
the irreversible change due to the initiation was to be found in the cell's 
genome. 
Three processes are capable of inducing an irreversible change in the 
cell's genome and functions: 
1. A change in the information in the DNA (somatic mutation theory) -
resulting in the production of "abnormal" proteins. 
2. A change in the control mechanism of the genome - affecting the ex-
pression of existing information in the DNA. 
3. The acquisition of new information in the DNA - e.g. viral incorpora-
tion. 
The somatic mutation theory for carcinogenesis was originally proposed by 
Boveri in 1914, long before the nature of carcinogenesis and the molecular 
structure of the genetic material were known. General support for the theory 
that initiation is caused by mutagenic events comes from the observation 
that most carcinogens are mutagens (McCann and Ames, 1975). Moreover, the 
mutation theory implies that all cells of a given tumour should be the des-
cendants of a single cell, and that the cancer is clonal in origin. With 
the use of inactivated polymorphic X-linked loci in cells of women (Fialkow, 
1976; Williams et al., 1983) it was shown that various tumours were indeed 
of clonal origin. 
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However, serious criticism has been raised against the mutation theory 
as the sole source of initiation. It has been shown that not all known 
carcinogens are mutagens (Rubin, 1976), and there is no good correlation 
between mutagenic activity of a compound and its carcinogenic action. 
In this context it is important to note that the impact of the mutagen, 
e.g. alkylation of nucleic acids (Jensen, 1978; Singer et al., 1978), is 
not necessarily irreversible. It was observed that the disappearance of 
ß-propiolacetone and methylbenzanthracene-induced adducts from DNA was too 
rapid to be explained by depurination or DNA turnover (Colburn and Bout-
well, 1968; Rayman and Dipple, 1973). Apparently active repair of DNA can 
take place. Bowden et al. (1975) demonstrated excision repair of DNA lesions 
induced in mouse skin by ultraviolet light. Thus, when the binding level or 
potency of an initiator is being considered, the rate and accuracy of re-
moval of the lesion by DNA-repair must be included in a rationalization of 
the effect of the initiator. The importance of DNA-repair mechanisms may be 
demonstrated by the disease xeroderma pigmentosum (XP). XP-patients have an 
impaired DNA-repair mechanism (Friedberg et al., 1979). As a result of this 
defect XP-patients are extremely sensitive to u.v. light induced mutations, 
and suffer from an incidence of skin cancer that is several thousand times 
higher than normal (Bridges and Strauss, 1980). Thus, the lesion induced by 
the initiator turns into a fixed mutation if it escapes DNA-repair (Trosko 
and Chang, 1978). Trosko et al. (1977) proposed that DNA-repair is involved 
in the initiating step of carcinogenesis, and that "error-prone" DNA-repair 
or replication mechanisms are the major causes of mutagenesis. 
Although there is abundant evidence that mutagenesis plays an important 
role in initiating carcinogenesis, the other two processes capable of in-
ducing irreversible changes in the cell's genome are also associated with 
neoplastic transformation. A change in the control mechanism of gene-ex-
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pression, as exemplified by the translocation of the c-myc oncogene (Dalla-
Fevra et al., 1983) or gene amplification (Benedict et al., 1975) has been 
shown to be involved in carcinogenesis. 
The acquisition of new genetic information has been demonstrated to 
play a role in virus-associated carcinogenesis. Several viruses have been 
found to induce various malignancies, including sarcomas, carcinomas and 
hematopoietic tumours (Weiss et al., 1982). These viruses were shown to 
have incorporated sequences derived from cellular genes (proto-onco-genes) 
which gave the particular viruses the ability to transform infected normal 
cells (Bishop, 1983). The transforming capacity of retroviruses has been 
demonstrated both in vivo and in vitro (Weiss et al., 1982, Aaronson, 
1983). 
In conclusion, all three processes capable of inducing irreversible 
changes in the genome have been found to be associated with carcinogenesis 
and may be regarded as mechanisms for Initiation. 
1.3.3 Promotion 
The two-stage model for carcinogenesis was based on the results of 
mouse skin carcinogenesis studies. Therefore, it is no surprise that most 
studies concerning the nature of tumour promotion were focussed on mouse 
skin. However, more recently, evidence was obtained that carcinogenesis is 
a stepwise process in many organs, 
a) Skin Tumour Promotion 
The introduction of croton oil as a powerful skin tumour promotor (Beren-
blum and Shubnik, 1947) and the isolation and identification of its tumour 
promotor active components, the phorbol esters (Van Duuren and Orris, 1965; 
Hecker and Schmidt, 1974) enabled investigators to study two-stage carcino-
genesis under defined and controlled conditions. Usually mouse skin carcino-
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genesis 1s Initiated with a single dose of dimethylbenzanthracene (DMBA) 
followed by two applications of TPA (12-0tetradecanoylphorbol-13-acetate) 
(Boutwell, 1974). In a remarkable experiment in which tumour promotion was 
performed with two different promoting agents, it was found that tumour 
yield was higher when first croton oil and later turpentine was given than 
when first turpentine and later croton oil were (Boutwell, 1964). Accor-
dingly, it was proposed that skin tumour promotion could be subdivided into 
two different stages. This concept was confirmed and elucidated further by 
Fürstenberger et al. (1981). Stage 1 can be induced by short term treatment 
with a "complete" promotor, such as TPA. Even a single application has 
turned out to be sufficient, provided the animal 1s subsequently treated by 
chronic application of an "incomplete" promotor (stage 2), usually a growth 
stimulator (Fig. 5). 
Mezerein and RPA, a semi-synthetic phorbolester, are called "incom-
plete" promotors because, by themselves, they have only a very weak pro-
moting capacity (Fürstenberger et al., 1981; Slaga et al., 1980). When 
applied, however, after a short-term exposure to TPA, they are able to pro-
mote the effects of TPA, resulting in skin tumour formation. 
Skin tumour promotion has been regarded as an entirely reversible pro-
cess. This concept had to be re-evaluated when Fürstenberger et al. (1983) 
demonstrated that the time interval between stage 1 and stage 2 promotion 
could be Increased up to at least 8 weeks, without a significant decrease 
in tumour yield, Implying Irreversibility of stage 1 promotion. 
The different characteristics of stage 1 and 2 promotion enabled in-
vestigators to discriminate between the various effects of TPA administra-
tion. Inflammation is a typical response of the skin after TPA treatment. 
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carcinogen 
B promoter, skin wound 
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Fig. 5. A scheme of three-stage tumorigenesis in mouse skin: 
1) Initiation-followed by a single (or a few) local application(s) 
of a complete tumour promoter (or wounding) does not give rise 
to tumour development within a time period of 12 weeks or more; 
2) a large number of tumours is obtained when initiation and 
limited promoter treatment is followed by chronical application 
of a hyperplasiogenic agent ("incomplete promoter"); 
3) treatment of initiated skin with an incomplete promoter alone 
is not tumorigenic; 
4) the effect of promoter treatment in stage 1 of promotion is 
virtually irreversible. 
However, when the promoting efficacy of different irritating agents was 
compared with their inflammation capacity, a relative poor correlation was 
found (Gschwendt and Hecker, 1974). Associated with inflammation, epidermal 
hyperproliferation seems to play an important role in tumour promotion. 
Tumour promotion was found to be completely inhibited when the TPA-induced 
stimulation of DNA synthesis during stage 1 was prevented by treatment of 
the animals with hydroxyurea (Kinzel et al., 1984). Thus, proliferation 
plays a role in stage 1 promotion. 
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Chronic treatment with incomplete promotors (stage 2) results in the 
induction of sustained epidermal hyperplasia (Sisskin et al., 1982) indi-
cating that proliferation is also involved in stage 2 promotion. TPA has 
also been demonstrated to inhibit intercellular communication between cells 
(Yancey et al.,1982), an effect which has been suggested to be an important 
determinant of malignant transformation (Enomoto and Yamasaki, 1984). Since 
incomplete tumour promotors exhibit the same properties, inhibition of 
intercellular communication is believed to be involved in stage 2 of skin 
tumour promotion. 
Studies on the molecular mechanism of skin tumour promotion have demon-
strated the existence of a phorbol-ester receptor (Drieger and Blumberg, 
1980; Ashendel et al., 1983a). Further investigations revealed the existence 
of a Ca +- and phospholipid-dependent, TPA-binding activity in the soluble 
fraction of mouse tissues, which paralleled their soluble protein kinase C 
activity (Ashendel et al., 1983b). The close correlation between binding 
affinity and promoting efficacy has led to the conclusion that receptor 
mediated activation of protein kinase C activity plays an important role in 
skin tumour promotion. Since the incomplete promotors mezerein and RPA have 
been found to exhibit a similar affinity to the receptor (Schmidt et al., 
1983) and to stimulate protein kinase C activity almost as powerfully as 
TPA (Gschwendt et al., 1983), it may be concluded that these reactions are 
related to stage 2 promotion. 
As far as the molecular mechanisms involved in stage 1 promotion are 
concerned, there is evidence to suggest that TPA exhibits a specific, high-
affinity binding to isolated nuclei and nuclear macromolecules in mouse 
epidermis (Perella et al., 1982). Moreover, it has been demonstrated 
(Dzarlieva-Petrusevska and Fusenig, 1985) that TPA induces chromosome 
aberrations in mouse keratinocyte cell lines. In addition, Kinsella and 
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Radman (1978) have shown that TPA induces sister chromatid exchanges. They 
suggested that TPA treatment may lead to genetic recombination, resulting 
in the expression of recessive genetic changes. This hypothesis would be in 
agreement with the reported irreversibility of stage 1 promotion. 
b) Liver Tumour Promotion 
The first clear demonstration that liver carcinogenesis could also be 
separated into stages was reported by Peraino et al. (1973a). In this study 
2-acetylaminofluorene (AAF) was fed at a concentration of 0.02% for 18 days 
to male albino rats to initiate carcinogenesis. Following the AAF feeding 
several groups of rats were exposed to 0.05% phénobarbital (a non-carcino-
genic agent). After 180 days, the tumour yield in the group fed only AAF 
was 20%; in the groups exposed to phénobarbital as well, tumour yield was 
70%, even though promotor treatment was started 30 days after the initia-
tion, thus clearly demonstrating the validity of the two-stage model for 
hepatocarcinogenesis. Further studies demonstrated that compounds such as 
DDT (Peraino et al., 1975) or PCB's (Kimura et al., 1976) could also pro-
mote hepatocarcinogenesis. In addition, Peraino et al. (1973b) showed that 
the incidence of "spontaneous" liver tumour formation in male and female 
C3H mice (50% and 10%, respectively, after one year) could be increased to 
100% for both sexes when the animals were fed on a diet containing 0.05% 
phénobarbital for the same period of time. 
Soon after the application of an initiating agent, particularly in rat 
liver, groups of altered cells, or foci, can be demonstrated since they ex-
hibit a variety of alterations (Färber and Cameron, 1980; Bannasch et al., 
1985). Very useful markers to detect these foci are the altered expressions 
of several enzymes, such as ATPase, y-glutamyl transpeptidase or glucose-6-
phosphatase (Schwarz et al., 1984; Buchmann et al., 1985). Evidence has been 
presented that these enzyme-altered foci are the precursors of hepatocellu-
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lar carcinomas (Watanabe and Williams, 1978; Pitot and Sirica, 1980). 
Tumour promotors such as phénobarbital have been shown to increase the 
proliferation rate of enzyme-altered foci, thus expanding the population of 
these altered cells (Pitot et al., 1980; Scherer and Emmelot, 1979). It has 
been shown that enzyme-altered foci respond more readily and more pro-
nouncedly to phénobarbital treatment than normal hepatocytes (Schulte-Her-
mann et al., 1986). These responses include enhanced DNA synthesis and the 
expression of microsomal enzyme systems. It can thus be suggested that 
tumour promotors alter gene expression and thus facilitate the expression 
of the neoplastic potential of initiated cells (Peraino et al., 1978). 
Hepatocarcinogenesis is considered to comprise three different and 
distinct stages: initiation - promotion - progression (Pitot and Sirica, 
1980). Progression, the stage in which the neoplasm becomes malignant, is 
usually accompanied by karyotypic changes, oncogene activation and biologi-
cal alterations resulting from changes in the genome (Pitot, 1986). The 
manifestation of a detectable tumourgenic enhancement 200 days after the 
cessation of a brief period of phénobarbital treatment (20 days) following 
AAF initiation, has led to the suggestion that phénobarbital produces irre-
versible changes in initiated cells (Peraino et al, 1977). Based on these 
and other findings, it has been put forward that liver tumour promotors, by 
selectively increasing the number of precursor cells, increase the risk of 
"spontaneous" progression at the genetic level, thus enhancing liver tumour 
formation (Scherer and Emmelot, 1979; Van Renselaer Potter, 1981). This 
view differs radically from that which is usually held for tumour pro-
motion, especially with respect to skin carcinogenesis. 
2.4 MICROSOMAL ENZYME INDUCERS 
2.4.1 General Aspects 
A variety of xenobiotic compounds, such as phénobarbital, DDT, a-HCH, 
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butylated hydroxitoluene (BHT) and dieldrin have been reported to enhance 
liver tumour formation in rats previously initiated with liver carcinogens 
(Peraino et al., 1973a, 1975, 1977; Schulte-Hermann; 1978). Chronic exposure 
to these compounds of various strains of mice susceptible to "spontaneous" 
liver tumour formation also enhances liver tumour formation (Walker et al., 
1973; Thorpe and Walker, 1973; Tomatis et al., 1972; Peraino et al., 1973b; 
Ito et al., 1973). In terms of two-stage carcinogenesis these compounds are 
regarded as tumour promotors. 
There is no apparent similarity in chemical structure between these com-
pounds. Their main common features are: 
1) Lipophilicity at physiologic pH, 
2) Induction of liver enlargement, 
3) Induction of drug*-metabo1ising enzymes 
4) Proliferation of smooth endoplasmic reticulum (SER). 
The changes in the liver induced by xenobiotics are usually not accom-
panied by evidence of liver damage and are reversible upon withdrawal and 
elimination of the compound (Wright et al., 1972, 1977; Schulte-Hermann, 
1974; Depiere and Ernester, 1976; Böhm and Moser, 1976). 
A characteristic change in laboratory animals exposed to xenobiotic 
compounds is the induction of liver enlargement (Barka and Popper, 1967; 
Schulte-Hermann, 1974). This may be attributed to hypertrophy (an increase 
in cell size without an accompanying increase in DNA content), to hyper-
plasia (an increase in cell number or an increase in cell size with a con-
comitant increase in DNA content) or to a combination of the two (Barka and 
Popper, 1967). The process in which an increase in cell size with a propor-
tional increase in DNA content is observed is called polyploidization and 
may be regarded as an arrested form of cell replication. Polyploidization 
is a typical feature of the liver. 
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The contribution of hypertrophy and hyperplasia to liver enlargement 
seems to depend on the properties of the inducers and on the species and 
strain of animal. In rats, dieldrin and phénobarbital induce predominantly 
hypertrophy, whereas a-HCH and BHT have been reported to induce mainly 
hyperplasia (Wright et al., 1972; Schulte-Hermann, 1971, 1974). In rats, 
dogs and rhesus monkeys, dieldrin-induced liver enlargement was mainly due 
to hypertrophy (Walker et al., 1978). In the mouse, however, both dieldrin 
and phénobarbital induced liver enlargement were reported to result from 
both hypertrophy and hyperplasia. Evidence has been presented that hyper-
plasia in mouse liver induced by xenobiotics can, at least partially, be 
attributed to polyploidization (Böhm and Noltemeyer, 1981; Schulte-Hermann, 
1979). 
Inducers of liver enlargement have been found to be substrates of the 
microsomal mono-oxygenase system of mammalian liver and were able to induce 
the activity of these enzymes (Conney, 1967; Wright et al., 1977). The 
mono-oxygenase or mixed-function oxidase systems catalyse the oxidative 
catabolism of lipophilic substrates and require NADPH and molecular oxygen 
for their action. This membrane bound system consists of an electron 
donating system (NADPH-cytochrome P-450 reductase, cytochrome b5 reductase 
and cytochrome b5), and iron-containing haemoproteins. On the basis of the 
spectral properties of the haemoproteins, this system is referred to as 
P-450 (Omura and Sato, 1964). The P-450 system metabolises not only endo-
genous substrates such as steroids or fatty acids but also a variety of 
lipophilic xenobiotics (Conney, 1967; Guette et al., 1972). Its very broad 
substrate specificity can, at least partially, be explained by the existence 
of many isoenzymes. In the rat liver 11 P-450 isoenzymes have been purified, 
all with different activities toward a number of specific substrates 
(Thomas et al., 1983; Ryan, 1984). The isoenzymes which are most frequently 
induced by xenobiotic compounds are the b, c, d and e forms (Table IV). 
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Table IV. INDUCTION OF CYTOCHROME P-450 ISOENZYMES 
Inducer Total Cytochrome Isoenzymes 
P-450 a b+e c d unknown 
(nmol/mg) (% of total amount of cytochrome P-450) 
none 
isosafrole 
3-methycholanthrene 
beta-naphtaflavone 
TCDD 
arochlor 1254 
gamma-chlordane 
phénobarbital 
SKF 525-A 
PCN 
0.86 
2.33 
1.83 
1.96 
2.51 
3.67 
1.88 
2.18 
2.26 
1.34 
6 
5 
14 
9 
13 
7 
4 
6 
4 
5 
4 
17 
1 
1 
1 
37 
46 
55 
35 
3 
3 
16 
78 
71 
60 
27 
3 
1 
4 
2 
5 
38 
24 
24 
20 
22 
1 
2 
1 
1 
82 
24 
-16 
-4 
7 
7 
46 
36 
56 
89 
The exact nature of the relationship between microsomal enzyme induction 
and liver tumour promotion is not known. However, Poland and co-workers 
have provided evidence for a receptor-mediated, liver tumour-promoting 
effect of microsomal enzyme induction. The aryl hydrocarbon hydroxylase 
(AHH) activity is generally used to determine the induction of the P-450 
c isoenzyme by polycyclic aromatic hydrocarbons, such as benzo(a)pyrene 
and methylcholantrene. One of the most potent liver tumour promotors, in-
ducing the P-450 c form (Table IV), is 2,3,7,8-tetrachlorodibenzo-p-dioxin 
(TCDD) (Van Miller et al., 1977; Pitot et al., 1980). Studying the relation-
ship between different chlorinated dibenzo-p-dioxins and their efficacy in 
inducing AHH activity, Poland and Glover (1976) were able to identify a re-
ceptor for these compounds. The ability of the different chlorinated di-
benzo-p-dioxins to induce AHH activity was found to be related to their 
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toxicity (Poland and Knutson, 1982). Interestingly, AHH activity (i.e. the 
P-450 c isoenzyme) cannot be induced in all mouse strains (Nebert and 
Gielen, 1972; Thomas et al., 1972). A mutation in the structural gene for 
the AH-receptor in DBA/2 mice has been shown to be responsible for the im-
paired responsiveness of these mice to microsomal enzyme induction by 
polycyclic aromatic hydrocarbons (Okey et al., 1979; Weaver et al., 1980). 
Moreover, it has been shown that these mice are also non-responsive to 
tumour promotion by these compounds. Poland et al. (1982) have also demon-
strated the existence of such a receptor in mouse epidermis and the cor-
relation of the existence of this receptor with tumour promotion. It would 
thus appear that liver tumour promotion by xenobiotic compounds may be 
mediated by receptors responsible for the induction of microsomal enzyme 
activity. 
1.4.2 Dieldrin 
Dieldrin was first synthesized in the laboratory in 1948, and commer-
cial production in the USA was first reported in 1950 (Galley, 1970). The 
only known use for dieldrin is as an insecticide, in 1972 it was estimated 
that 80% of the USA production of dieldrin was used on corn crops and 
about 10% for termite control (IARCmonographs, 1974). 
The chemical name of dieldrin is: endo-exo isomer of 1,2,3,4,10,10-
hexachloro-6,7-epoxi-l,4,4a,5,6,7,8,8a-octahydro-l,4,5,8-d1methano naphtha-
lene, its chemical structure is shown in Figure 6. 
Dieldrin 1s a solid chemical with a melting point of 176-177°C. Its density 
is 1.75 mg/ml; it is not soluble in water, but readily dissolves in acetone, 
benzene or DMS0. 
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Fig. 6. Chemical structure of dieldrin. 
The effects of dieldrin on tumour formation have been studied in mice, 
rats, dogs and monkeys. In a series of experiments, reported by Walker et 
al. (1973), Thorpe and Walker (1973), and Tennekes (1979) CF-1 mice were 
exposed to 0, 0.1, 1.0 or 10.0 ppm dieldrin in the diet. It was found that 
dieldrin enhanced liver tumour formation in all of the treatment groups. 
It should be noted however, that the CF-1 mouse strain is characterized by 
a high incidence of "spontaneous" liver tumours. Several studies with 
dieldrin in the rat have been published. Fitzhugh et al. (1964) reported a 
non-significant increase of liver tumours in Osbourne-Mendel rats exposed 
to 0.5, 2 or 10 ppm dieldrin in the diet. In female CFE rats exposed to 
0.1, 1.0 or 10.0 ppm dieldrin in the diet no increase in tumour formation 
was observed (Walker et al., 1969). Two studies with dieldrin in Osbourne-
Mendel rats (National Cancer Institute, 1978a) and in Fisher rats (National 
Cancer Institute, 1978b) also failed to provide evidence for a carcinogenic 
effect of dieldrin on rat liver. 
There are few and limited data on the possible carcinogenicity of 
dieldrin in mammalian species other than rats and mice. Walker et al. 
(1969) reported that a 2-year oral exposure in dogs did not result in liver 
tumour formation in these animals. In another study rhesus monkeys were fed 
on diets containing 0, 0.01, 0.1, 0.5, 1.0, 1.75 or 5.0 mg dieldrin/kg body 
weight for periods up to 6.5 years. No obvious alterations in general struc-
ture in the livers of these animals were observed (Wright et al., 1978). 
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Epidemiological observations on the state of health of a total of 826 
workers involved in the handling of dieldrin in a plant of Shell Nederland 
Chemie N.V. at Pernis (Rotterdam) have not demonstrated any persistent ad-
verse effects on the health of these workers (Hoogdam et al., 1965; Jager, 
1970). No deaths due to liver cancer have been observed (Jager, 1970; 
Versteeg and Jager, 1973). 
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QUANTITATIVE ASPECTS OF ENHANCED LIVER TUMOUR FORMATION IN CF-1 MICE BY 
DIELDRIN. 
Henk Tennekes, Ben van Ravenzwaaij and H. Werner Kunz 
The German Cancer Research Centre, Institute of Biochemistry, 
Im Neuenheimer Feld 280, D-6900 Heidelberg, FRG. 
SUMMARY 
The dose:response characteristics of dieldrin-mediated enhancement of liver 
tumur formation in CF-1 mice were analysed, using existing tumour data from 
chronic feeding studies at six levels of continuous exposure, involving a 
total of more than 1,500 animals. The dose-response relationship can be 
expressed as 
D x • T x = D 0 • T 0 = constant (I) 
where T = the median liver tumour induction period in control CF-1 mice, 
T = the median liver tumour induction period in dieldrin-treated mice at a 
dose level D , D = the background dose equivalent for the induction of 
"spontaneous" liver tumours, D = the sum of background dose (D ) and 
actual dieldrin dose (S ). 
The relationship, which is a Druckrey equation (D • Tn = constant) where 
. n = 1, indicates that 1) the velocity of liver tumour development is pro-
portional to the daily dose level (D ), 2) the total tumorigenic dose is 
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constant across all doses, 3) the effects of dieldrin on the neoplastic 
process in mouse liver are essentially irreversible and cumulative, and 4) 
there is no evidence for a threshold level. However, when 6 « D , the 
actual contribution of dieldrin to tumour formation is expected to be 
negligible. 
INTRODUCTION 
A variety of xenobiotic compounds are known to induce characteristic changes 
in the livers of laboratory animals. These changes include: (1) liver en-
largement, usually as a result of cell enlargement, polyploidisation or cell 
replication, (2) induction of drug-metabolising enzymes, and (3) prolifera-
tion of the smooth endoplasmic reticulum (1-6). Such changes are not 
usually accompanied by evidence of liver damage, and are reversible upon 
withdrawal and elimination of the compound (5,6). Consequently, this pheno-
menon is likely to be an adaptive response of liver to increased functional 
demands. However, chronic exposure of various strains of mice to microso-
mal enzyme inducers, such as dieldrin, phenobarbitone, DDT and hexach-
lorocyclohexane (HCH)-stereoisomers, may cause an increase in the incidence 
of liver tumours (7-12). Phenobarbitone, DDT, butylated hydroxytoluene (BHT), 
and a-HCH have also been shown to promote the formation of rat liver 
tumours from lesions previously initiated by hepatocarcinogens (13-16). By 
analogy, it has been suggested that microsomal enzyme inducers do not exert 
an intrinsically carcinogenic effect on mouse liver but function by 
enhancing the effect of a pre-existing oncogenic factor, which may be of 
environmental or genetic origin (5,7). 
It is conceivable, in principle, that enhancers of carcinogenesis and in-
trinsically carcinogenic compounds exhibit different dose-response charac-
teristics. The doserresponse characteristics of chemical carcinogens, in 
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Single dose and chronic exposure experiments, have been elucidated by 
Druckrey and his associates (17-22) 
D • Tn = constant (1) 
where D = daily dose, T = the median tumour induction period, and n = an 
exponent, always greater than 1. 
Thus, carcinogenic response is defined as the median time period required 
for a constant end-point of the carcinogenic process. Equation (1) descri-
bes a quantitative relationship between the median velocity of tumour for-
mation (or tumour-associated death) and the dose level of the carcinogen 
(Druckrey, personal communication). Velocity is measured in units of 
reciprocal time, and, accordingly, the most appropriate form of Druckrey's 
relationship is 
(1/T)n = (constant) • D (2) 
or 
1/T = (constant) • D 1 / n (3) 
The dose:response characteristics of putative carcinogenesis enhancers have 
been studied with various model compounds, particularly with phénobarbital 
(23-27), but no mathematical equivalent has emerged sofar. We have recently 
reported a non-linear relationship between the logarithm of daily dieldrin 
dose and the logarithm of the median liver tumour induction period in CF-1 
mice (25). This non-linearity contrasted with equation (1). However, in the 
dieldrin study, the likelyhood is that the velocity of tumour formation was 
determined by multiple factors, i.e. by combination of dieldrin dose and 
background factors (responsible for liver tumour development in untreated 
control CF-1 mice). In mathematical terms 
1/TX - D 0 + 6 X (4) 
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where Tx = median liver tumour induction period at a dieldrin dose level 6 
and D = a background dose equivalent for liver tumour development in 
control CF-1 mice (when 6 = 0 ) , the velocity of which will be denoted as 
1/T . Accordingly, dieldrin dose relates to the increase in the velocity of 
liver tumour formation only, i.e. to 
(1/TX) - (1/T0) (5) 
The aim of the present analysis was to elucidate a possible quantitative 
relationship between dose and response, as defined above. 
MATERIALS AND METHODS 
Details on animal experiments, liver pathology and statistical procedures 
have been reported previously (8,9,25), but some important aspects are 
briefly reviewed. Treatment of CF-1 mice with dieldrin commenced at the age 
of three weeks. The animals were palpated weekly as from after 16 weeks of 
treatment to detect the presence of intra-abdominal masses, and killed when 
the enlargement was considered to be detrimental to health. The treatment 
period up to that point was referred to as the liver tumour induction 
period. Liver tumours were classified as adenomas (nodular growths of solid 
cords of parenchymal cells) or carcinomas (papilloform and adenoid growth 
with cells proliferating in confluent sheets with necrosis, increased mito-
sis, and sometimes associated metastases to the lungs). No significant sex 
difference in the tumorigenic response of liver to dieldrin could be 
detected (25), and tumour data for males and females within groups were 
combined. Details of statistical procedures have been described previously 
(25). 
RESULTS 
Most of the liver tumours observed in control CF-1 mice and in treatment 
groups up to the level of 5 ppm dieldrin in the diet were classfied as li-
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ver adenomas (Table 1) . At higher dose leve ls , i . e . in the 10 and 20 ppm 
treatment groups, appproximately 2/3 of the l i ve r tumours were c lass i f ied as 
carcinomas (Table 1) . 
Table I. Liver tumour data from long-term feeding studies with dieldrin in CF-1 mice (conducted by A.I.T.Walker and E.Thorpe at Shell Toxicology Laboratory, 
Sittingbourne, Kent) 
Dieldrin Initial Number of Number of 
(p.p.m.) number of mice with mice with 
mice liver adenomas liver carcinomas 
0 
0.1 
1 
2.5 
5 
10 
20 
586 
244 
228 
58 
60 
324 
38d 
84 
48 
52 
27 
36 
119 
8 
11 
10 
16 
4 
8 
190 
12 
Median tumour 
induction period 
(weeks) 
131 (128-139)b 
122 (120-133) 
117 (115-121) 
108 (106-115) 
93 (91-99) 
66 (65-67) 
44 (41-48) 
Median total 
dosea 
(mg/kg) 
0 
8.5 
81.9 
189 
325 
462 
616 
Carcinoma induction period 
(10% incidenccl 
(weeks) 
120 (>116) 
119 (>117) 
112 (>107) 
c 
_ c 
60 (59-62) 
39 (<44) 
'Calculated on the basis of an average daily food intake of 100 g/kg bodyweight. 
bNumbers in parentheses indicate 95% confidence intervals. 
cCarcinoma data considered too scant to warrant analysis. 
dSixteen animals in this treatment group died from acute intoxication within the first 13 weeks of treatment. 
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Fig. 1. Left: cumulative proportion of CF-l mice with liver tumours versus dieldrin exposure time, at indicated dose levels (log-probit). The exposure time 
interval up to 50% liver tumours was designated as the median liver tumour induction period. Right: cumulative proportion of CF-1 mice with liver 
carcinomas versus dieldrin exposure time, at indicated dose levels (log-probit). The exposure time interval up to 10% liver carcinomas was designated as the 
liver carcinoma induction period. 
A substantial proportion of the animals exposed to 20 ppm d ie ld r i n 
died from acute in tox icat ion wi th in the f i r s t 3 months of experimentation. 
As with any non-l iver tumour bearing animal, these early losses were 
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classified as incidental deaths. The cumulative incidence of liver 
tumours (adenomas or carcinomas) as well as the cumulative incidence 
of liver carcinomas (only) is shown in figure 1. Both data sets showed an 
excellent fit to the log-normal distribution, and linear regressions were 
virtually parallel. The median liver tumour induction period was defined as 
the treatment interval up to a 50% incidence of liver tumours. Median liver 
carcinoma induction periods could not be established in all but two dose 
groups (10 and 20 ppm, respectively). Instead, the time interval up to 
a 10% incidence of liver carcinomas was used as an indicator of the car-
cinoma induction period (Table 1). The relationship between dieldrin dose 
and the acceleration of tumour formation was analysed with median liver 
tumour induction periods as well as with liver carcinoma induction periods. 
Both indicators of neoplastic response yielded similar results (see below). 
Acceleration of liver tumour formation and dieldrin dose 
The velocity of liver tumour formation and of liver carcinoma formation ver-
sus dieldrin dose is shown in figure 2. Tumorigenic response was found to 
be linearly related to dose: 
(1/TX) = (1/T0) + K • 6X (6) 
The proportionality factor of dose (K), which is the tangens of the slope, 
is defined as the ratio of the velocity of tumour development in control 
mice (1/T ) , and the background dose equivalent ( n 0), i.e. 
1 / To 
Do 
= (1/(D0 ' T0)) (7) 
D was found to be equipotent to a level of approximately 10 ppm dieldrin in 
the diet (figure 2). Equations (6) and (7) lead to 
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(1/TX) = (1/T0) + (Sx / D 0 • T0)) (8) 
or 
(1/TX) = (1/T0) • ((D0 + S x) /D 0) O) 
The sum of background dose (D ) and dieldrin dose (6 ) w i l l be denoted as 
D . This modification leads to the equation 
D • Tx = DQ • TQ = constant (10) 
0.025 
Î 0.020 
0.015 
• 
c 
O 
s 
Z3 
0010 
> Û005 
0.001-
' I ' ' ' ' I 
0 5 10 15 20 
DIELDRIN (ppm in diet) 
5 10 15 20 
DIELDRIN (ppm in diet) 
Fig, 2. Left: the reciprocal median liver tumour induction period (-0-) (= the velocity of tumour development) versus dieldrin dose. The dieldrin-associated 
increase in the velocity of tumour development ( - • - ) , as defined in the text, versus dieldrin dose is also shown. The proportionality factor of dieldrin dose, 
which is the tangent of the angle, is defined as the ratio of the reciprocal median liver tumour induction in untreated CF-1 mice (1/T0) and the background dose 
(D0). which is equipotent to a level of 10.2 p p m . dieldrin in the diet. Right: the reciprocal liver carcinoma induction period (-0-) (= the velocity of 
carcinoma development) versus dieldrin dose. The dieldrin-associated increase in the velocity of carcinoma development (- • -) versus dieldrin dose is also 
shown. The proportionality factor of dose was defined as described above. The background dose (D0) for carcinomas was found to be equipotent to a level of 
10.0 p.p.m. dieldrin in the diet. 
Accordingly, there is a linear relationship between the negative logarithm 
of the sum of background dose and actual dieldrin dose (- log D ) and the 
logarithm of the median l iver tumour induction period (log T ), as is shown 
in figure 3. These results demonstrate that the kinetics of l iver tumour 
formation in dieldrin-treated CF-1 mice are consistent with the Druckrey 
61 
relationship, i.e. with equation (1). 
However, in the dieldrin study, the value of the exponent of time (n) 
equals 1, i.e. there is no time-associated acceleration of the neoplastic 
process in CF-1 mouse liver. The implication is that, in contrast to car-
cinogens (n > 1), the total tumorigenic dose ( = D • T ) is constant 
across all doses. Dieldrin's actual contribution to the total tumorigenic 
dose is dependent on the acceleration of liver tumorigenesis, however. 
Equation (10) can be modified to read as 
<Do + Sx> ' Tx = Do ' To (») 
or 
S 'T = D 'T - D 'T (12) 
x x o o o x v ' 
or 
S ' T = D • (T - T ) (13) 
x x o v o x'
 y
 ' 
In words, the shorter the median liver tumour induction period in dieldrin-
treated mice, i.e. the higher the daily dieldrin dose level, the greater 
will have been dieldrin's contribution to the total tumorigenic dose 
(table 1). This relationship is illustrated in figure 4. 
DISCUSSION 
The analysis yielded a simple equation to describe the dose:response 
characteristics of enhanced liver tumour formation in dieldrin-treated 
CF-1 mice. The observed quantitative relationship indicates that the total 
tumorigenic dose, defined is the product of the sum of daily background and 
dieldrin dose (D ) and the median liver tumour induction period (T ), is 
constant across all doses. 
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Fig. 3. The sum of background dose and dieldrin dose versus the median 
liver tumour induction period ( - • - ) , and the liver carcinoma induction 
period (-0-) , respectively, on logarithmic coordinates. The tangent of the 
angle (45°) is 1, in both cases. Linearity leads to equation (10). 
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ACCELERATION OF TUMOUR! GEN ESI S (days) 
Fig. 4. Total dieldrin intake (t>x x Tx), as a function of the acceleration of 
tumourigenesis (T0 - Tx). Left: liver tumours (50%). Right: liver carcinomas 
(10%). Linearity leads to equation (13). Broken line denotes the total tumourigenic 
(carcinogenic) dose, which is constant, irrespective of the daily dieldrin dose level. 
Table II. The theoretical basis of dose-response relationships, according to H.Druckrey and K.Küpfmüller (1949)a 
Reversibility of 
receptor binding 
Receptor binding in 
relation to compound 
concentration 
Reversibility 
of the effect 
Effect in relation to 
receptor binding 
Effect in relation to 
compound concentration 
Dose-response characteristics 
T R - 0 
T R - 0 
T R - 0 0 
T R - O O 
C R - C 
C R ~ C 
C R - I cd t 
C R - | c dl 
T r - 0 
T r - o o 
T r - 0 
T t - o o 
E~ CR 
E - j C R dt 
E - CR 
E - I C R dt 
E -
E -
E -
E -
c 
c dt 
c dt 
Jc dt 
Dose-dependent 
( ' Konzentrationsgi ft ' ) 
Dose- and time-dependent 
('c.l.-Gift') 
Dose- and time-dependent 
Cet.-Gift') 
Dose- and time-dependent 
time-associated acceleration 
('Verstärkerwirkung') 
4TR— = time constant for the reversibility of receptor binding; Tr— = time constant for the reversibility of the effect; c = compound concentration; CR 
concentration of receptor binding; E = effect. 
The constancy of the product of concentration and time (needed to produce a 
speci f ic ef fect ) was established for many drugs by Clarke in a remarkable 
monograph published half a century ago (28). A theoret ical basis for 
" c . t . = constant" was provided by Druckrey and Küpfmüller in 1949 (18). 
These authors inferred that doserresponse relat ionships are essent ia l ly 
determined by two processes, i . e . 1) the r e v e r s i b i l i t y of binding to speci-
f i c receptors in target ce l l s , and 2) the r e v e r s i b i l i t y of the ef fect of 
receptor binding (pharmacological action or t o x i c i t y ) . The r e v e r s i b i l i t y of 
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any process is indicated by time constants (in this case, TR for binding to 
specific receptors, and T for the effect of receptor binding) (table 2). 
When both of these time constants approach zero, i.e. when both processes 
are quickly reversible, the effect will be strictly dose-dependent 
("Konzentrationsgift") (table 2). However, when one of two processes is 
irreversible, the effect will depend on dose as well as on the duration of 
treatment ("ct.-Gifte") (Table 2). This has now been demonstrated to be 
the case for the neoplastic response of mouse liver to dieldrin (equation 
(10)). 
Presumably, the sustained but essentially reversible interaction of diel-
drin with critical receptors in CF-1 mouse hepatocytes results in irrever-
sible progression (read: acceleration) of an ongoing neoplastic process. 
Finally, Druckrey and Küpfmüller predicted that the irreversibility of both 
processes would lead to time-associated acceleration of the effect ("Ver-
stärkerwirkung") (Table II). Such dose-response relationships were subse-
quently established for chemical carcinogens of different organotropy 
[equation (1)] (19-22). The interaction of ultimate carcinogen(s) with 
critical receptors in the genome ('initiation') as well as the adverse ef-
fects of such receptor binding on the regulation of cell division and cyto-
differentiation ('expression of neoplastic potential') are likely to be ir-
reversible processes. Thus, there would appear to be a fundamental differ-
ence in the nature of receptor binding between the non-genotoxic carci-
nogenesis enhancer dieldrin (29-31) and liver carcinogens, such a diethyl -
nitrosamine, where n = 2.3 (19), or diethanolnitrosamine, where n = 4.7 
(22). It is interesting to note, in this context, that the dose-response 
relationship for dieldrin is very similar to that observed for 4-dimethyl-
aminoazobenzene (4-DAB), where n = 1.1 (17,19). There is evidence to indi-
cate that 4-DAB is a very poor initiator compared with diethylnitrosamine 
or diethanolnitrosamine (32). 
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Druckrey's equation (1) holds for single-dose as well as chronic-exposure 
experiments with chemical carcinogens, and identical n-values (2,3) have 
been ovserved in single-dose experiments with N-nitroso-N-ethylurea (21) 
and in chronic-exposure experiments with diethylnitrosamine (19). The 
'initiation' of carcinogenesis is immediate, i.e., almost timeless in 
comparison with the latent period of tumors. The implication is that the 
second process, i.e., the expression of neoplastic potential, may well 
determine the kinetics of tumour development. Sharply delineated stages of 
functional development of hepatocytes, e.g., at birth and at the 'late 
suckling' period (23), have been found to be associated with high suscepti-
bility to a single dose of a liver carcinogen (34,35). Apparently, neopla-
stic potential is more readily expressed when, due to drastic changes in 
the animals' environment, initiated hepatocytes are committed to embark 
on a major process of functional development. Likewise, microsomal enzyme 
inducers, such as dieldrin, might enhance tumourigenesis by creating a hig-
her level of functional commitment in their target cells ('functional 
stress'). 
The results of a previous study (36) indicated that dieldrin is unlikely to 
exert its tumourigenic action by exacerbating the effect of a potent envi-
ronmental carcinogen. No difference in liver tumour incidence was observed 
between CF-1 mice bred, reared and maintained on a semi-synthetic diet and 
filter-paper bedding, and those exposed to a conventional diet and sawdust 
bedding. Dieldrin was found to be equally tumourigenic in both environments 
(36). These experimental data suggest that the origin of background tumours 
may be genetically-linked and transmitted from one generation to the next. 
If so, this neoplastic potential is only slowly expressed, under normal 
circumstances. The median liver tumour induction period in untreated con-
trol CF-1 mice (T0) is 2.5 years, which exceeds the average lifespan of the 
animals by ~ 6 months. The background dose (D0) was found to be equipotent 
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to a level of ~ 10 p.p.m. dieldrin in the diet. 
It is conceivable that D 0 reflects a certain level of naturally occurring 
or endogenous substances, which express intrinsic neoplastic potential in 
mouse hepatocytes in the course of time. Equation (10) is consistent with 
the view that the effects of background tumorigens and dieldrin are additi-
ve, and that there is no threshold level for the tumour-promoting action of 
dieldrin. However, when the actual level of dieldrin in the diet is very 
low in comparison with the level of background tumorigens, dieldrin's con-
tribution to liver tumour development is expected to be negligible. 
Accordingly, there may be a rational for a practical 'no effect' level of 
carcinogenesis enhancers, such as dieldrin. 
Dieldrin has been found to be non-tumourigenic in experimental species 
which are less susceptible to spontaneous development of liver tumours 
(37,38). The strain differences observed in the tumourigenic response of 
mouse liver to dieldrin (E. Thorpe, unpublished observations) and to phé-
nobarbital (39) would also seem to be related to a different genetic predi-
sposition to spontaneous tumourigenesis. Such observations are consistent 
with the view that pre-existing levels of tumour susceptibility in human 
populations could be critically important in defining virtually safe levels 
of tumour-promoting agents. 
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SUMMARY 
It has recently been demonstrated that the enhancement of liver 
tumour formation in CF-1 mice by dieldrin is determined by the 
product of (tumorigenic) dose and time ("d • t = constant"). 
Apparently, the effects of dieldrin on the neoplastic process in 
CF-1 mouse liver are essentially irreversible and cumulative. This 
concept contrasts with the reported reversibility of dieldrin-
induced subcellular changes and the absence of genotoxic activity 
or potential of dieldrin in mouse hepatocytes. 
The results of the present study confirm that liver enlargement, 
microsomal enzyme induction, pyruvate kinase isoenzyme changes and 
nuclear polyploidization induced in mouse liver by dieldrin are 
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entirely reversible after withdrawal and elimination of the 
compound. In contrast, the tumour data obtained in a limited 
dieldrin exposure experiment reported by Walker et al. (Food 
Cosmet. Toxicol., 11_, 415-431, 1972) and those obtained in a 
"delayed dieldrin exposure experiment", i.e. dieldrin treatment 
commencing after control diet feeding for a period of 60 weeks, are 
shown to be consistent with the concept that dieldrin exerts 
irreversible and cumulative effects on liver tumour development in 
CF-1 mice. The apparent paradox between the reversible effects of 
dieldrin on subcellular changes and the essentially irreversible 
effects on liver tumour formation can be reconsiled by assuming 
that any increase in the velocity of an ongoing process by whatever 
means of action (reversible or irreversible) for whatever period of 
time leads to an increased liver tumour risk. 
INTRODUCTION 
Continuous exposure of CF-1 mice to dieldrin results in a sustained 
induction of liver microsomal enzyme systems, as well as liver 
enlargement associated with cellular hypertrophy and increases in 
total liver DNA (1-3). These changes are not accompanied by 
evidence of liver damage, and have been reported to be entirely 
reversible upon withdrawal and elimination of the compound (1-3). 
Consequently, this phenomenon is likely to be an adaptive response 
of mouse liver to increased functional demands imposed by dieldrin. 
However, prolonged exposure of CF-1 mice to dieldrin results in 
enhancement of liver tumour formation. This effect can be likened 
to a time shift in the kinetics of "spontaneous" liver tumour 
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formation (4-7). A similar time shift has recently been 
demonstrated for the enhancement of nuclear polyploidization in 
CF-1 mouse liver by dieldrin (S). 
The dose response characteristics of enhanced liver tumour 
formation in CF-1 mice by dieldrin can be expressed as (6): 
(do + dx) x t = constant (1) 
where t = the median liver tumour induction period in CF-1 mice, 
do = the background dose (in dietary dieldrin units) for the 
induction of spontaneous liver tumours, and dx = the actual 
dieldrin dose. This empirical dose response relationship (a 
Druckrey relationship, where n=l) indicates that the median total 
tumorigenic dose is constant across all (daily) doses, and that 
the effects of the tumour promotor dieldrin on the neoplastic 
process in CF-1 mouse liver are irreversible and cumulative. This 
concept contrasts with the reported reversibility of dieldrin-
induced subcellular changes in mouse liver (1-3). Furthermore, 
there is strong evidence that the tumorigenic action of dieldrin 
is not mediated through direct interaction of the compound or one 
of its metabolites with cellular DNA (2,9,10). It would appear 
unlikely, therefore, that the dose-response relationship reflects 
irreversible and cumulative binding to critical receptors in mouse 
hepàtocytes at the genetic level. The apparent paradox can be 
reconciled by assuming that sustained but essentially reversible 
interaction of dieldrin with critical receptors in mouse 
hepatocytes results in irreversible progression (read : 
acceleration) of an ongoing neoplastic process (6). 
The objective of the present study was to examine the validity of 
this theoretical concept. The reversibility of microsomal enzyme 
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induction, liver enlargement, nuclear polyploidization and pyruvate 
kinase isoenzyme shifts induced by dieldrin was examined 1 and 2.5 
months after a 2-month treatment period with 10 ppm dieldrin in the 
diet. The validity of equation (1), was tested on its consistency 
with liver tumour data obtained in a limited dieldrin exposure 
experiment in CF-1 mice previously reported by Walker et al. (4). 
Equation (1) also implies that liver tumour formation would be 
associated with a constant total tumorigenic dose. To test this 
implication the total median tumorigenic dose was calculated for an 
experiment where CF-1 mice were exposed to 10 ppm dieldrin after a 
treatment free period of 14 months, and compared to those obtained 
in continuous exposure experiments at 6 dieldrin dose levels. 
MATERIALS AND METHODS 
Animal Experiments 
CF-1 mice were kindly provided by Shell Research Ltd,Sittingbourne, 
Kent, UK. The colony was maintained under SPF conditions at Ivanovas, 
Kieslegg, FRG. Weanling female CF-1 mice were supplied to the German 
Cancer Research Centre upon request. The animals were allocated to 
groups and acclimatised for 1 week. Dieldrin treatment commenced at 
«4-5 weeks of age. The animals were expdsed to 10 ppm dieldrin in a 
C-1000 diet (control and experimental diets were prepared by Altromin 
GmbH, Lage, FRG).Diet and water were given ad libitum. 
Reversibility Experiment with Dieldrin 
Approximately 20 male mice were exposed to 10 ppm dieldrin in the 
diet for 2 months and placed on a control diet, thereafter. Six 
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animals pier group were killed for liver analysis 2, 3 and 4.5 
months after the onset of treatment. 
Delayed Dieldrin Treatment Experiment 
Female animals were placed on a control diet for 60 weeks, and 
exposed to 10 ppm dieldrin in the diet, thereafter. The animals 
were palpated twice weekly as from the onset of dieldrin treatment 
to detect the presence of intra-abdominal masses, and killed when 
the enlargement was considered to be detrimental to health. The 
time period up to that point will be referred to as the liver 
tumour induction period. 
Sacrifice and Preparation of Liver Tissue 
Animals were weighed and killed by cervical dislocation. Livers 
were quickly excised, the gall-bladder was removed and the tissue 
was weighed. Approximately one-half of the liver was chilled in 
ice-cold 0.25 M Suerose/TKM (0.05 M Tris-HCl, pH 7.4, 0.025 M 
KCl and 0.005 M MgCl 2), for the assessment of polyploidization. 
The remaining one-half of liver tissue was chilled in ice-cold Mic-
I buffer (0.25 M Saccharose, 5.5 mM EDTA and 0.02 M Tris-HCl pH 
7.5), for liver biochemistry (cytochromes P-450 and b5 concentration 
and pyruvate kinase isoenzyme activities). After a few minutes, the 
liver tissues were blotted and weighed. 
Assessment of polyploidization 
Liver nuclei were isolated as described by Blobel and Potter (11). 
Nuclear pellets were resuspended in 0.35 ml TKM buffer, and fixed 
by injection into tubes containing 12 ml absolute ethanol at -20° C. 
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Flow Cytometry 
DNA analysis was performed using 4 '-6-diamidino-2-phenylindole 
dihydrochloride (DAPI) as the quantitative DNA fluorochrome (12). 
Flow cytometry was carried out with a Leitz Wetzlar flow cytometer. 
DAPI excitation was achieved with a u.v. light source (bandpass 
filter 340-380 nm). DAPI fluorescence was collected through a high 
pass filter (430 nm). The data obtained were displayed as frequency 
distributions of fluorescence intensity ( a measure of nuclear DNA 
content). In each case 40,000 nuclei were measured. The percentage 
of diploid and polyploid nuclei were corrected for doublets and 
higher aggregates of nuclei according to Beck (13). 
Determination of Cytochromes Content 
Liver tissue was homogenised with 4 volumes of Mic-I buffer in a 
Potter-Elvehjem homogeniser (10 passes, 1400 rpm). The homogenate 
was centrifuged at 20, 3500 and 7000xg for 10 min, respectively. 
The 7000xg supernatant was collected and centrifuged at 104,00ûxg 
for 1 h. The microsomal pellet was resuspended in Mic-II buffer 
(0.12 M KCl and 0.05 M Tris-HCl pH 7.5) and again centrifuged at 
104,000xg for 1 h. The microsomal pellet was resuspended in Mic-II 
buffer to yield a final protein concentration (determined according 
to Lowry et al (14) using bovine serum albumine as a standard) of 
2 mg/ml. Cytochromes b5 and P-450 concentrations were determined 
according to Omara and Sato (15), using a molar extinction 
difference of 105 and 91 cn-'nM-1 for cytochromes b5 and P-450, 
respectively. 
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Assay for Pyruvate Kinase Isoenzymes 
The proportion of L- and K-pyruvate kinase (PK) was determined in 
the soluble fraction by measuring the pyruvate kinase activity in 
the presence and absence of 5 mM tryptophane, as described by 
Ibsen et al. (16). Tryptophane completely inhibits K-PK activity, 
while L-PK retained 85% of its activity (as measured by purified L-
pyruvate kinase). Thus, the pyruvate kinase activity in the 
presence of tryptophane x 1.18 was used to calculate the L-PK 
activity. 
Statistics 
The age-specific liver tumour incidence in the delayed dieldrin 
treatment experiment was calculated with Kaplan-Meier non-
parametric estimates of liver tumour probability based on censored 
data (17), censorship being imposed on death due to other causes, 
natural or artificial. The fit of the tumour incidence data to a 
log-normal distribution was subsequently assessed. 
RESULTS 
Reversibility Experiment 
A dietary dieldrin concentration of 10 ppm administered to CF-1 
mice for a period of 2 months resulted in a 43% increase in 
relative liver weight, a 118% increase in cytochrome P-450 content 
and a 94% increase in cytochrome b5 content. The L-pyruvate kinase 
activity was decreased by approximately 15% , whereas the K-
pyruvate kinase activity was 20% higher relative to untreated 
controls. Nuclear polyploidization, expressed in the proportion of 
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o c t a p l o i d n u c l e i , had i n c r e a s e d 88% as a r e s u l t of t h e d i e l d r i n 
t r e a t m e n t (Table 1 ) . 
The d i e l d r i n - i n d u c e d changes i n r e l a t i v e l i v e r we igh t , microsomal 
cytochrome P-450 and b5 c o n c e n t r a t i o n s , as w e l l a s t h e changes i n 
p y r u v a t e k i n a s e isoenzyme a c t i v i t y were found t o be compl e t e l y 
r e v e r s i b l e w i t h i n one month a f t e r c e s s a t i o n of d i e l d r i n t r e a t m e n t . 
The enhancement of p o l y p l o i d i z a t i o n by d i e l d r i n , q u a n t i t a t e d by t h e 
p r o p o r t i o n of o c t a p l o i d n u c l e i , t h e p e r c e n t a g e of 16c n u c l e i be ing 
<0.3% i n a l l g roups excep t i n t h e 10 ppm t r e a t m e n t group a t t h e 2 -
month exposu re i n t e r v a l (1 .9%) , a l s o d i s a p p e a r e d w i t h i n 2 . 5 months 
of c o n t r o l d i e t f e ed ing (Table 1 ) . 
Table 1 . The r e v e r s i b i l i t y of subce l lu lar changes in mouse l i v e r induced by d i e l d r i n 
PARAMETER TIME - INTERVAL 
a f t e r 2 months of a f t e r 1 month a f t e r 2.5 months 
d i e l d r i n treatment of regression of regression 
Control 10 ppm Control 10 ppm Control 10 ppm 
Relat ive l i v e r weight 4.73 + 0.48 6.78 + 0.58** 4.8B + 0.29 4.90 + 0.41 4.29 + 0.23 4.70 + 0.27 
Cytochrome P-450 0.61 + 0.20 1.33 + 0.25** 0.5B + 0.14 0.62 + 0.08 0.80 + 0.08 0.62 + 0.10 
2 •* 
Cytochrome b5 0.34 + 0.08 0.66 + 0.12 0.28 + 0.06 0.27 + 0.03 0.42 + 0.03 0.42 + 0.06 
3PK-L 45.9 + 5.1 38.8 + 4.0** 73.8 + 9.8 76.7 + 6.6 79.1 + 7.7 78.5 + 8.1 
3PK-K 13.3 + 1.7 15.9 + 2.0* 20.2 + 2.7 19.1 + 3.2 21.7 + 1.7 20-.8 + 4.3 
Polyploidization 9.4 + 2.3 17.7 + 2.4** 10.4 • 1.9 12.5 + 2.4* 11.6 + 2.1 12.8 + 1.9 
a: n=6 in all cases 
1: liver to bodyweight ratio (%) 
2: nmol/mg microsomal protein 
3: nmol pyruvate/mg soluble protein/min 
4: percentage octaploid (8c) nuclei 
, : P«c0.05, ,. : P<0.01 (significance of the difference between treatment and controls) 
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Limited Dieldrin Exposure Experiment 
In the limited dieldrin exposure experiment in CF-1 mice 
reported by Walker et al. (4), the animals were exposed to 10 ppm 
dieldrin in the diet for periods of up to 64 weeks. The incidence 
of liver tumours was assessed in the survivors after 104 weeks. 
The current objective is to examine whether the liver tumour data 
obtained in this experiment are consistent with equation (1). This 
examination was accomplished along the following lines of 
reasoning : 
i) Definition of the Tumorigenic Dose. 
Equation (1) implies that in a limited exposure experiment the 
following relation must hold: 
dx . tx = d* • t (2) 
where dx = the (actual) dieldrin dose administered during a limited 
period of time 
tx = the (actual and limited) dieldrin exposure time 
d* = the (hypothetical) dieldrin dose level during the 
entire observation period (in this case 104 weeks) 
t = the total observation period (104 weeks) 
The tumorigenic dose level in a limited exposure experiment is 
consequently defined as the sum of the background dose level (do) 
and the hypothetical dieldrin dose level during the entire 
observation period (d"). 
ii) Definition of the Mathematical Model. 
The mathematical liver tumour risk model to be used for the 
prediction of the liver tumour incidence after 104 weeks in the 
limited dieldrin exposure experiment must be consistent with 
n 
equation (1). Dose-response relationships of the form: d • t = 
constant (Druckrey relationships) have been shown to be 
corollary of the extended Weibull model (17): 
m k 
-{«+0 d) • t 
P = 1 - s (3) 
where P = probability of a (liver) tumour at time t 
d = dose 
t = observation time 
m = shape parameter for dose 
k = shape parameter for the time to a (liver) tumour 
« = parameter measuring the background (liver) tumour 
probability (Po) with « = -ln(l-Po) 
8 = scale parameter 
The dose:response relationship for dieldrin enhanced liver tumour 
formation in CF-1 mice (equation (1)) is a Druckrey relation (where 
n=l), thus the (dieldrin) adapted form of the Weibull model for 
tumour incidence would be: 
m k 
-(«+ß(do + dx) »t 
P = 1 - e (4) 
In Druckrey's studies (19-23), the background tumour rate was 
essentially zero, which means that the parameter « = 0. In the 
continuous dieldrin exposure study, the background factors (do) 
leading to "spontaneous" liver tumours in CF-1 mice were found to 
be equipotent to a level of approximately 10 ppm dieldrin in the 
diet (6). The background tumour incidence already being accounted 
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for by "do", a concept put forward by Albert and Altshuler (24) 
reduces « to 0 and leads to the following adapted form of the 
Weibull model: 
m k 
B(do + dx) • t 
P = 1
"
e
 (5) 
or, in the case of a limited dieldrin exposure experiment: 
m k 
„ - 3(do + d* ) « t 
P
 =
 1
 -
 e
 (6) 
iii) Tes-Ç of the Mathematical Model on Copsistency with 
Equation (1) 
At a defined liver tumour risk, say P = 0.5, equation (4) can be 
reduced to : 
1/m , . 
- In G 5 k / m 
( ^il^H--) = (do + dx) . t (?) 
B 
Thus, equation (1) will be implied by equation (4) only if the 
value of the shape parameter for the time to a liver tumour (k) 
will be similar to the shape parameter for dose (m). This premiss 
was tested using the liver tumour data obtained with dieldrin in 
continuous exposure experiments with CF-1 mice (4,5) (fig. 1.). 
The tangents of the angles observed for the dose-risk relationship 
at 70 and 100 weeks of exposure were 8.1 and 7.5 respectively, 
leading to an average value of 7.8 for the shape parameter for dose 
(m). The tangents of the angles observed for the time-risk 
ao 
relationship at the actual dieldrin dose levels of 20 , 10, 5, 1 and 
0 ppm in the diet were 7.3, 7.6, 7.8, 10.6 and 8.4, leading to a 
mean value of 7.8 + 0.4 for the shape parameter for the time to a 
liver tumour (k) (the k-value for the 1 ppm data set was 
disregarded). 
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Figure 1. The fit of the liver tumour data obtained with dieldrin 
in continuous exposure experiments with CF-1 mice (-4,5) to the 
extended Weibull model (males and females were combined in the 
absence of a sex-difference in tumour response). 
P = liver tumour risk (0-1) 
D = the sum of the daily background dose (do) and actual dieldrin 
dose (dx) in ppm in the diet 
T = time in weeks 
Left : Dose : tumour-risk at constant time (70 and 100 weeks). 
Right : Time : tumour-risk at constant dose (0, 1, 5, 1Û and 20 ppm). 
Accordingly, the analysis yielded similar values for k_ and m, 
indicating that equation (1) is a corollary of equation (4). With 
known values of do, dx , k and m the value of 3 can be calculated 
using the median liver tumour induction periods. 
iiii) Application of the Mathematical Model for the Prediction of 
Liver Tumour Risk in the Limited Dieldrin Exposure Study 
The prediction with equation (5) of the observed incidence of liver 
tumours in surviving animals after 104 weeks (with exposure periods 
of 0 , 2, 4, 8, 16, 32 and 64 weeks respectively) , was accurate for 
6 out of 7 groups (Table 2). Thus, the results of the limited 
dieldrin exposure study are consistent with equation (1) and 
support the concept that the effects of dieldrin on the development 
of mouse liver neoplasia are entirely irreversible and cumulative. 
Delayed Dieldrin Exposure Experiment 
Dieldrin treatment at a dose level of 10 ppm in the diet 
commenced after 60 weeks of control diet feeding. The cumulative 
proportion of CF-1 mice with palpable liver tumours is shown in 
Figure 2. The time interval associated with a cumulative frequency 
of 50% liver tumours, i.e. the median liver tumour induction 
period, was found to be 95 weeks (Fig. 2.). 
The median liver tumour induction period in untreated control 
female CF-1 mice has been shown to be 129 weeks (6). Thus the 
administration of 10 ppm dieldrin in the diet after 60 weeks of 
control diet feeding accelerated the median appearance of liver 
tumours by 34 weeks, and effectively halved the median time to 
liver tumour development of 69 weeks for control CF-1 mice after 60 
Table 2. Observed and expected incidence of liver tumours in male 
CF-1 mice fed 10 ppm dieldrin for up to 64 ueeks and sur-
ving for 104 ueeks 
Group Dieldrin 
No. Treatment 
Period 
(ueeks) 
Number of 
Sypvivors 
After 104 
Ueeks 
Liver tumour incidence 
After 104 Ueeks 
Observe 
2 
2 
1 
4 
4 
6 
13 
d Expected 
2.1 
1.7 
1.5 
2.0 
3.4 
6.3 
12.9 
1 
2 
3 
4 
5 
6 
7 
0 
2 
4 
8 
16 
32 
64 
18 
13 
10 
10 
11 
10 
13 
The equation used is 
P = 1 0-fl <d0 + d x )
7
'
8
 t7'8 
— 25 
where G = a scale parameter ( 3.16x10 ) 
d = the backgroud dose equivalent for the induction of 
"spontaneous" liver tumours in CF-1 mice found to be 
equipotent to a level of 10 ppm dieldrin in the diet 
d = the (hypothetical) dieldrin dose level over the entire 
observation interval t 
t = the total observation period, in this case 104 ueeks 
P = the liver tumour probability, 
leading to the following P-values after 104 ueeks : Group 1: 0.116; 
group 2: 0.133; group 3: 0.152; group 4: 0.197; group 5: 0.313; 
group 6: 0.631; group 7: 0.994 
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weeks. It is interesting to note , in this context, that continuous 
exposure of female CF-1 mice to 10 ppm dieldrin in the diet as from 
the age of 4-5 weeks has been shown to result in a mediari liver 
tumour induction period of 64 weeks (Fig. 2.), which is one-half of 
the median liver tumour induction period in control CF-1 mice (12$ 
weeks). 
i • ' • ' i " i 
60 100130 
TIME (weeks) 
Figure 2. The cumulative proportion of female CF-1 mice with liver 
tumours versus time at indicated treatment levels (log-probit). T^e 
time period up to 5051 liver tumours was designated as the median 
liver tumour induction period. 
• : continuous exposure as from the age of 3 weeks (da.'ta source-
references 4,5) 
o : Exposure to 10 ppm after a treatment free period of.' 60 weeks 
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After 95 weeks, the total dose administered to CF-1 mice equals: 
:x = 10 (ppm) x 95 (weeks) + 10 (ppm) 
= 1300 (ppm.weeks) 
35 (weeks) 
The corresponding total tumorigenic doses observed in the 
continuous exposure experiments with dieldrin in CF-1 mice were 
(actual daily dieldrin dose levels in parentheses) 1310 (controls), 
1232 (0.1 ppm), 1287 (1 ppm), 1350 (2.5 ppm), 1395 (5 ppm), 1320 
(10 ppm) and 1320 (20 ppm). 
These data support the concept that liver tumour formation in CF-1 
riptprminpri by a defined total tumorigenic dose, is déterminée 
regardless of the daily tumorigenic dos« Levei- a nd the time 
DISCUSSION 
The induction of subcellular changes in CF-1 mouse liver by 
dieldrin was found to be entirely reversible, which is in agreement 
with previously reported data (1,3). Relative liver weight, 
cytochr* P-450 and b5 concentrations as well as the isozyme 
composition of pyruvate Knàse 'returned fo control levels within i 
month after cessation Of dieldrin treatment. These findings suggest 
that the reported 'changes in CF-J mouse liver induced by dieldrin 
in the initial phases of treatment reflect an adaptation of the 
liver to increased functional demands. Nuclear polyploidisation 
reached control values within 2.5 months of control diet feeding. 
In contrast, the effects of dieldrin on the expression of (pre-
R5 
existing) oncogenic potential in mouse liver appears to be entirely 
irreversible. Three lines of evidence can be presented in support 
of this contention. 
Firstly, the empirical dose-response relationship discovered for 
the enhancement of liver tumour formation by dieldrin (equation 
(1)) indicates that the total tumorigenic dose, which is defined 
as the product of the sum of daily background dose and actual 
dieldrin dose (do + dx) and the median tumour induction period, is 
constant for all dieldrin treatment levels. 
Secondly, the dose-response relationship is consistent with the 
results of a limited exposure experiment in CF-1 mice (Table 2.). 
These results indicate that limited exposures to dieldrin lead to 
an excess liver tumour risk, the extent of which is proportional to 
the dieldrin exposure time interval. Similar results have been 
reported for the effect of limited exposures to phénobarbital of 
Sprague-Dawley rats pre-treated with the liver carcinogen 2-
acetyiaminofluorene (25). Progressive increases in the duration of 
phénobarbital treatment (begun 1 week after carcinogen treatment) 
advanced the time at which tumour enhancement occurred and 
similarly increased overall tumour incidence levels. 
Thirdly, the enhancing effects of dieldrin on liver tumour 
formation in mouse liver are independent of the time of onset of 
dieldrin treatment. Liver tumour formation in CF-1 mice exposed to 
dieldrin after a treatment-free period of 60 weeks was associated 
with a median total tumorigenic dose virtually identical to 
those seen in chronic studies, with 6 levels of dieldrin exposure. 
The results of the present study are consistent with the concept 
advanced previously (6), that sustained but essentially reversible 
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Isolation of Liver Nuclei 
Animals were weighed, and killed by cervical dislocation between 9-10 a.m. 
Livers were quickly excised, the gallbladder was removed, and the tissue 
was chilled in ice-cold 0.25 M sucrose/TKM (0.05 M Tris - HCl, pH.7,4 
(20 °C), 0.025 M KCl and 0.005 M MgCl2), for a few minutes. The livers were 
blotted and weighed. Liver nuclei were isolated as described by Blobel and 
Potter (16). Nuclear pellets were resuspended in 0.35 ml TKM buffer, and 
fixed by injection into tubes containing 12 ml absolute ethanol at -20 °C. 
Flow Cytometry 
DNA analysis was performed using DAPI (4'-6-diamidino-2-phenylindole-
dihydrochloride) as the quantitative DNA fluorochrome (17). Flow cytometry 
was carried out with a Cytofluorograph 30 (Ortho Diagnostic Systems) con-
nected to a computerized multichannel analyzer (Plurimat, Intertechnique). 
The UV lines (351 nm and 364 nm) of an argon ion laser were used for DAPI 
excitation. DAPI fluorescence was collected through a low pass filter at 
450 nm. The data obtained were displayed as frequency distributions of 
fluorescence intensity (a measure of nuclear DNA content). In each case 
40,000 nuclei were measured. The percentages of diploid and polyploid 
nuclei were corrected for doublets and higher aggregates of nuclei, 
according to Beck (18). 
RESULTS 
The proportion of octaploid nuclei increased linearly in all groups during 
the observation period of approximately one year (table 1, figure 1). The 
proportion of 16C nuclei was very low (<0.3%), except in the 5 and 10 ppm 
treatment groups at the 9-month exposure interval (0.7 %, and 1.9 % 
respectively). These results indicate that, with two exceptions, the losses 
of octaploid nuclei due to the formation of 16C nuclei were negligible. 
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Table 1. Percentage octaploid nuclei at different 
Dieldrin dose Treatment 
(p.p.m. indict) 1
 8 5 m o m h s 
0 4.1 ± 2.0(6)" 
0.1 
1 
5 
10 12.3 ± 2.1 (6) 
treatment intervals 
3 months 
4.8 ± 1.7 (11) 
5.5 ± 0.7 (5) 
6.2 ± 1.9 (9) 
8.8 ± 2.5 (10) 
12.7 ± 1.6 (9) 
Interval 
6 months 
6.8 ± 2.3 (11) 
7.3 ± 1.8 (9) 
7.9 ± 1.3 (8) 
10.4 ± 1.7 (7) 
14.5 ± 2.9 (7) 
9 months 
8 5 ± 1.9 (5) 
9.0 ± 2.3 (5) 
9.4 ± 1.1 (5) 
12.5 ± 1.5 (6)h 
16.1 ± 2.1 Of 
14 months 
11.5 ± 2.3 (7) 
-
-
-
-
'Number of animals/group is indicated in parentheses. 
""Value includes 0.7% 16C nuclei. 
'Value includes 1.9% 16C nuclei. 
20 
z 
o 
o 
t U O -
o 5 
110 PPM DIELDRIN | 
CONTROL! 
— i i i — i — | — i — i — i — i — | — 
5 10 15 
EXPOSURE TIME IN MONTHS 
O 
5 10 
DIELDRIN (PPM IN DIET) 
Fig. 2. Dietary dieldrin concentration-related differences (relative to 
controls) in octaploid liver nuclei (%) at various exposure time intervals 
(1.85. 3, 6 and 9 months, also see Table I). 
Fig. 1. Increases in octaploid liver nuclei (%) in response to dietary dieldrin 
concentration (p.p.m.) and exposure time. 
Accordingly, the changes in the proportion of octaploid nuclei (A(8C)) 
were used as an indicator of the kinetics of polyploidisation in liver 
parenchyma within the period of experimental observation. 
The enhancement of polyploidisation by dieldrin (measured in "steady-
state" situations) was found to be proportional to dietary concentration 
(figure 2), and independent of the duration of dieldrin exposure. Poly-
ploidisation was analysed in untreated control CF-1 mice and found to be 
proportional to time (age) (figure 3). These results show that the kinetics 
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5 10 
TIME (MONTHS) 
Fig. 3. Age-associated increases in octapioid liver nuclei in control mice 
(%). The percentage of octapioid nuclei in livers of control CF-1 mice at 
the 1.85 months exposure interval was used as the base line. 
of polyploidisation (= the changes in the proportion of octapioid nuclei) 
can be expressed in ppm dieldrin in the diet (d) as well as in units of 
time (t) (figures 2, 3): 
A (8C) = kj x d = k 2 x t (1) 
where k1 and k- are constants. 
When polyploidisation is expressed in ppm dieldrin in the diet then 
d = (k2/k1) x t (2) 
This relationship is illustrated in figure 4. The implication of equation 
(2) is that the enhancement of polyploidisation by dietary dieldrin can be 
likened to a "time-shift" in polyploidisation associated with ageing. The 
extent of this time-shift which takes place in the initial phases of diel-
drin treatment, i.e. before "steady-state" ist reached, is proportional to 
the dietary dieldrin concentration as indicated by the parallelism of the 
linear regressions in figure 1. Age-associated polyploidisation when 
expressed in dietary dieldrin concentrations can be viewed as the response 
of mouse liver to the (cumulative) action of a constant concentration of 
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toxic substances during time (t), where c which be equivalent to 
d/t = 0.8 ppm dieldrin/month = 0.026 ppm/day, according to equation (2). 
5 10 
TIME (MONTHS! 
Fig. 4. PolyploidLzation in CF-1 mouse liver parenchyma (expressed in 
p.p.m. dieldrin in the diet) versus time. Age-associated increases in 
octaploid nuclei in control mice (O) were expressed in dietary dieldrin 
concentrations using the linear regression shown in Figure 2. Dieldrin-
induced increases in octaploid nuclei ( • ) were expressed in units of time 
using the linear regression shown in Figure 3. Linearity leads to equation 
(2). 
50 100 
EXPOSURE TIME (WEEKS) 
Fig. 5. Polyploidization in mouse liver parenchyma as a function of 
indicated dietary dieldrin concentrations and time (equation 3). Age-
associated polyploidization is expressed in units of dietary dieldrin 
concentration (p.p.m.), using equation (2). • , Median liver rumour 
induction period (= 50% incidence); O , time to a 10% incidence of liver 
carcinomas. 
Polyploidisation associated with dieldrin exposure as well as with ageing 
(~ d + ct) is illustrated in figure 5. Ploidy status at the (known) expo-
sure time interval associated with a cumulative frequency of 50 % liver 
tumours (adenomas or carcinomas) or 10 7. liver carcinomas (6) can be esti-
mated for each dietary dieldrin concentration and for non-dieldrin-treated 
controls. The results are visualised in figure 5, and suggest a virtually 
constant ploidy status at the time of liver tumour (carcinoma) formation in 
each group. 
DISCUSSION 
The enhancement of polyploidisation in CF-1 mouse liver by dieldrin, 
analyzed in "steady-state" situations was found to be proportional to 
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dietary dieldrin concentation, and independent of dieldrin exposure time. 
The absence of an "exposure time" effect on the enhancement of polyploidi-
sation indicates that, in "steady-state", the level of interaction of 
dieldrin with specific receptors does not change in the course of time. A 
constant and time-independent level of receptor binding implies, that 
1n "steady state", the velocity of association of dieldrin with specific 
receptors will be equal to the velocity of dissociation from these recep-
tors (19). 
Accordingly, this type of receptor binding is likely to be reversible upon 
withdrawal and elimination of the compound. This concept Is consistent 
with the available evidence on the reversibility of polyploidisatlon 
Induced by microsomal enzyme inducers (10,12,20 van Ravenzwaay, unpublished 
results). Thus, the enhancement of polyploidisation by microsomal enzyme 
Inducers would seem to be determined by the steady state concentration at 
the site of Interaction with specific receptors ("Konzentrationsgift"), 
Table II. Age- and 
Polyploidization 
effector 
Dieldrin 
Age(ing) 
dieldrin-related polyploidization as a function of specific receptor binding 
Reversibility of 
receptor binding 
r R - o 
Receptor binding 
in relation to 
compound 
concentration 
CK~C 
CR - j C d/ 
Reversibility 
of the effect 
T.-O 
T, - 0 
.b 
Effect in 
relation to 
receptor binding 
E~ CB 
E~ CR 
Effect in 
relation to 
compound 
concentration 
E ~ c 
£ - I c d / 
Dose—response 
characteristics 
Dose-dependent 
('Kcmzent rations-
gift') 
Dose- and time-
dependent 
('ct.-Gift') 
*rR — time constant for the reversibility of receptor binding; T, — time constant for the reversibility of the effect; c = compound concentration at the site of 
interaction with receptors; CR = concentration of receptor binding; £ = effect, i.e. polyploidization; l = exposure time. 
"This concept is based on the theories developed by Druckrey and Küpfmüller (19). 
Polyploidisation associated with ageing, as assessed in control mice, was 
found to be linearly related to time. Equation (2) is consistent with the 
concept that age-associated polyploidisation is a result of irreversible, 
and, therefore, cumulative interactions of toxic agents with specific 
receptors (table 2). Age-associated polyploidisation can be regarded 
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as a function of the product of a constant concentration of toxicants 
and time ("c.t.-Gift"), as shown in figure 4. 
These views are consistent with the progressive nature of age-associated 
polyploidisation. It is interesting to note, in this context, that the 
ploidy changes induced in rodent liver by carcinogens, such as dimethyl-
nitrosamine, aflatoxin B1, and 3'-methyl-4-dimethylaminoazobenzene have 
been reported to persist after discontinuation of treatment (21,22,23). 
This evidence may suggest similarities in the mechanisms of age-associated 
and carcinogen-induced ploidy changes. 
Polyploidisation (expressed in ppm dieldrin in the diet) at the median time 
to liver tumour development (= 50 % incidence) or at the time of a 10 % 
carcinoma incidence was estimated for each dietary dieldrin concentration 
and for non-dieldrin-treated controls, and found to be virtually constant 
across all groups (figure 5). At the time of a 50 % liver tumour incidence 
there would be a level of polyploidisation of 22.5 ± 0.8 ppm dieldrin in 
the diet; at the 10 % of a liver carcinoma incidence the level of poly-
ploidisation would be 21.4 ± 0.5 ppm dieldrin in the diet. 
The interference that at the time of tumour formation all groups would 
display the same degree of polyploidisation suggests a strong relationship 
between tumour formation and polyploidisation. The molecular mechanism is 
clearly a matter of conjecture, but some aspects can be discussed. The 
enhancement of polyploidisation by microsomal enzyme inducers, such as 
dieldrin, may be triggered to meet an increased requirement for particular 
organ-specific activities (gene dosage) i.e. drug metabolism and SER proli-
feration. 
If the rapid duplication of genetic material during the adaptation of the 
liver to increased functional demands would be followed by (some) nuclear 
devisions (and chromosomal redistributions) in the steady-state situation, 
heterozygous mutations could turn homozygous as has been pointed out by 
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Kinsella and Radman (24). In this way recessive oncogenic information could 
become phenotypically manifest (20). 
The duplication of genetic information in polyploidisation could also be 
triggered to save the expression of organ-specific functions from irrever-
sible damage to functional units in the genome, a concept which has been 
advanced previously by Medvedev (25) and Gahan (26). This concept could be 
reflected by the observed age-associated increase in polyploidisation. 
The effect of dieldrin treatment on liver-tumour formation in CF-1 mice 
can be viewed as a "time-shift", in "spontaneous" tumour formation (6). 
A similar "time-shift" is apparent in the enhancement of polyploidisa-
tion by dieldrin (figure 1 and figure 4). Judged by ploidy status, dieldrin 
appears to create a dose-dependent "time-gap" between chronological and 
biological age of mouse liver in the initial phases of treatment. The data 
are consistent with the view that tumour formation is imminent at a 
constant biological age of mouse liver and that tumour promoters may 
operate by advancing the biological age of their target organ in the ini-
tial phases of treatment. Thus, the close similarities in the kinetics of 
polyploidisation and tumour formation in livers of CF-1 mice exposed to 
dieldrin suggest that the analysis of ploidy status may serve as an aid to 
perspective in assessing risks posed by exposure to liver tumour promoters. 
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CHAPTER 2.4 
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DIELDRIN INDUCED CHANGES IN ISOENZYME COMPOSITION IN THE LIVERS 
OF CF-1 MICE 
Ben van Ravenzwaay, Hilda J. M. Toussaint and Rolf L. Schmitt 
The German Cancer Research Centre, Institute of Biochemistry, 
Im Neuenheimer Feld 280, D-6900 Heidelberg, F.R.G. 
SUMMARY 
The isoenzyme composition of lactic dehydrogenase (LDH), 
pyruvate kinase (PK) and alanine-amino transferase was determi-
ned in the livers of CF-1 mice, exposed to 0, 5 or 10 ppm 
dieldrin in the diet, over a period of 14 months. This study 
was carried out to evaluate a previously advanced concept in 
which the liver tumour promotor dieldrin was though to advance 
the biological age of CF-1 mouse liver. It was found that oral 
dieldrin exposure induced a dose-dependent shift towards the 
fetal typies of lactic dehydrogenase and pyruvate kinase, with-
in 1.5 months after initiation of treatment. After the initial 
shift, no additional dieldrin-dependent changes were found in 
CF-1 mouse liver throughout the experimental observation 
period of 14 months. Thus, the initial shifts in isoenzyme 
composition of LDH and PK would appear to reflect the 
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adaptation of the liver to increased functional demands imposed 
by the dieldrin treatment. Within liver nodules, observed 
after 14 months of 10 ppm dieldrin treatment, for both PK 
and LDH a further shift towards fetal isoenzymes was observed. 
No evidence for a gradual shift of isoenzyme activity between 
liver nodules and normal dieldrin treated liver was found. 
The expression of the cytoplasmic A-alanine-amino transferase 
isoenzyme was found to decrease with age, in untreated control 
mice. Dieldrin treatment enhanced this process in a dose 
dependent way. These data suggest that dieldrin treatment can 
accelerate age-dependent changes in gene-expression. Since the 
CF-1 mouse strain is characterized by age-related liver tumour 
development, dieldrin may operate as a liver tumour promotor 
in these mice by advancing the biological age of its target 
organ. The observed shift towards fetal isoenzymes may 
facilitate the expression of the intrinsic neoplastic potential 
of CF-1 mouse liver. 
INTRODUCTION 
The CF-1 mouse strain is characterized by the development of 
"spontaneous" liver tumours when they reach an advanced age. 
Continuous treatment with microsomal enzyme inducers, such as 
drugs, food additives and pesticides, enhances liver tumour 
development in these mice (Thorpe and Walker, 1973; Tennekes 
et al.,1981). Dieldrin was found to enhance liver tumour 
formation in CF-1 mice in a dose-dependent way (Tennekes et 
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al., 1985). 
We recently found that nuclear polyploidization of hepato-
cytes in untreated control CF-1 mice increases proportionally 
with time. The contribution of dieldrin to nuclear poly-
ploidization consists in a dose dependent enhancement of 
polyploidization shortly after initiation of treatment. A 
comparative analysis of polyploidization and liver tumour 
formation in dieldrin treated CF-1 mice revealed that liver 
tumour formation would be associated with a constant level of 
polyploidization (van Ravenzwaay et al., 1985), suggesting 
a relationship between polyploidization and tumour formation. 
Since polyploidization is an age dependent process (Shima and 
Sugahara, 1976) its enhancement by dieldrin might reflect ad-
vanced biological ageing. Accordingly it could be hypothesi-
zed that tumour promotors, such as dieldrin, could advance 
the biological age of their target organ and thus accelerate 
liver tumour formation. The present study was carried out to 
evaluate this hypothesis. 
In many cases total enzyme activity can be attributed to 
the combined action of its distinct isoenzymes . With regard 
to this study, it is important to note that different iso-
enzymes are expressed in the various phases of life (fetal, 
neonatal, adult and old). Changes in isoenzyme composition 
could therefore serve as a parameter to elucidate a possible 
relationship between dieldrin treatment and advanced biologi-
cal ageing. Over a period of 14 months the isoenzyme composi-
tion of three different isoenzyme systems was determined to 
study this question. 
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Lactic dehydrogenase (LDH) {EC. 1.1.1.27) has five iso-
enzymes, H4 -, H3M-, HaMa-, HM=,-, and M„ -LDH. These are 
composed of the two subunits, H and M, which are coded by two 
separate genes (Lalley et al., 1978; Market, 1968). In fetal 
liver the M* isoenzyme is the predominant form (Farron et al. 
1972). In the course of ageing the ratio of M- to H-subunits 
has been reported to decrease (Singh and Kanungo, 1968). In 
many neoplastic tissues a shift towards the M isoenzyme has 
been reported (Fischer et al.,1983). 
Different forms of pyruvate kinase (PK) (E.C. 2.7.1.40) 
named L-, M- and K-PK have been found in mammalian tissues 
(Ibsen and Trippet, 1972). In normal adult liver L-PK is the 
prevalent form, though K-PK is also present (Hall and Cottam, 
1978). In fetal liver and in hepatocarcinomas K-PK has been 
shown to be the most active form (Farron et al., 1972; Yanagi 
et al., 1984). K- and L-PK are produced by two different genes 
(Moore and Bulfield, 1981; Peters et al., 1981). 
Cytoplasmic alanine amino transferase (AAT )(EC. 2.6.1.2) 
has two isoenzymes (A and B) which are under separate genetic 
control (Chen and Giblett, 1971). In adulthood both types are 
present, while in young rats only A-AAT has been found, in old 
ones only B-AAT (Kanungo et al., 1978). 
MATERIALS AND METHODS 
Animals 
CF-1 mice were kindly provided by Shell Research Ltd, 
Sittingbourne, Kent, UK. The colony was maintained under SPF 
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conditions at Ivanovas GmbH, Kieslegg, FRG. Weanling female 
CF-1 mice were supplied to the German Cancer Research Centre 
upon request. The animals were allocated to groups and accli-
matised for 1 week. Dieldrin treatment commenced at 4-5 weeks 
of age. The animals were exposed to 0,1,5 and 10 ppm dieldrin 
in a C-1000 diet (control and experimental diets were pre-
pared by Altromin GmbH, Lage, FRG). Diet and water were given 
ad libitum. 
Preparation of soluble fractions from nodular and non-nodular 
liver tissues 
All chemicals used were obtained from Sigma, with the 
exception of ADP, NADH and phosphoenol pyruvate which were 
obtained from Boehringer, Mannheim. Animals were weighed and 
then killed by cervical dislocation between 9 and 10 a.m. 
The livers were quickly excised,the gall bladder was removed 
and the liver tissue was chilled in ice-cold 0.25 M sucrose/ 
TKM (0.05 M Tris-HCl, 0.025 M KCl and 0.005 M MgCl2, pH 7.4) 
for a few minutes. One part of the liver was blotted, 
weighed and, if present, liver nodules were dissected free 
from the surrounding normal liver tissue. Hereafter liver 
nodules and normal liver tissue were separately prepared 
using the same methods for both tissues. The other part of 
the (normal) liver was used for histochemical analysis. The 
liver tissues were homogenized with 4 volumes of 0.25 M 
sucrose/TKM in a Potter-Elvehjem homogeniser (10 passes, 1400 
rpm). The homogenate was centrifuged at 104,000xg at 4 C° for 
1 h. The resulting supernatant was used for the assays. 
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Protein content of the supernatant was determined according 
to Lowrey et al. (1951), using bovine albumine serum (BSA) as 
a standard. 
Assay for pyruvate kinase isoenzymes 
The proportion of L- and K-PK was determined by measuring 
the pyruvate kinase activity in the presence and absence of 5 
mM tryptophane, as described by Ibsen et al. (1975). Trypto-
phane completely inhibits K-PK activity. while L-PK retains 
85% of its activity (as measured by purified L-PK). Thus the 
pyruvate kinase activity in the presence of tryptophane x 
1.18 was used to calculate the L-PK activity. 
Electrophoresis 
Lactic dehydrogenase and alanine-amino transferase iso-
enzyme composition were determined by means of cellulose 
acetate (Sartorius) electrophoresis, using a Biotec-Fischer 
electrophoresis tank. Lactic dehydrogenase electrophoresis 
and staining were carried out according to Meera Khan (1971), 
with some minor modifications. Cellulose acetate sheets were 
incubated in the buffer solution, to which 0.5 mg BSA/ml 
buffer was added, for 10 min. Circa 200 /jg of soluble protein 
fraction were loaded on the sheets. Electrophoresis was per-
formed for 1.25 h at 60 V. Stained cellulose acetate sheets 
were subsequently analysed with a thin-layer chromatogram 
scanner (KM3-Zeiss Instruments) at 510 nm. This instrument 
was coupled to an integrator (Minigrator, Spectra-Physics) to 
quantitate the isoenzyme composition. The proportion of M to 
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H subunit3 was calculated using the detected isoenzyme acti-
vity, and multiplying this activity with the proportion of M 
and H subunits in the 5 isoenzymes (e.g. NU = 100% M-subunit, 
M3H= 75% M- + 25% H-subunit etc.). 
The expression of cytoplasmic alanine-amino transferase 
isoenzymes was studied using cellulose acetate electrophore-
sis. Before electrophoresis, the sheets were incubated in the 
buffer solution, to which 0.5 mg/ml BSA was added, for 10 min. 
The buffer solution contained 0.055 M Tris-borate (pH 8.9). 
Electrophoresis was performed for 1.5 h at 90 V. The staining 
medium contained 0.1 M KPO^ (pH 7.3), 10 mM «-ketoglutarate, 
10 mM alanine, 4 mM NADH and 15 units lactic dehydrogenase. 
Staining was carried out in the dark for 16 min at 37 O-'. 
Stained sheets were photographed under the light of a short-
wave length light source. 
Histochemical analysis 
Serial sections of 10 (jm were prepared at -15 C. on a 
cryostat microtome and used for the enzyme histochemical pro-
cedure. Glucose-6-phosphatase activity was demonstrated 
according to the method of Wachstein and Meisel (1956). Three 
sections of each liver were projected (magnification 45-fold) 
and digitized using a manual optic picture analyser (Kontron, 
Digicon, Munich, FRG.) and the amount of G-6-Pase deficient 
preneoplastic foci was subsequently quantitated. 
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RESULTS 
Cytoplasmic alanine amino transferase isoenzymes 
Adult, 3-month-old untreated control CF-1 mice were found 
to have two distinct cytoplasmic alanine-amino transferase 
isoenzymes. At the age of 14 months the slower migrating A-
isoenzyme could no longer be detected (Fig. 1). 
^ORIGIN 
B * Af 
Figure 1 - Electrophoresis of cytoplasmic alanine-amino 
transferase isoenzymes (A and B) on cellulose acetate 
from livers of dieldrin treated CF-1 mice. 
Lane 1, 3-month-old untreated controls 
Lane 2, 3 months treatment, 5 ppm dieldrin 
Lane 3, 3 months treatment, 10 ppm dieldrin 
Lane à, 14-month-old untreated controls 
These findings are in agreement with the studies of Kanungo 
et al. (1978). Three months of treatment with 5 ppm dieldrin 
considerably decreased the activity of the A-isoenzyme. Treat-
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ment wi th 10 ppm d i e l d r i n fo r t h e same p e r i o d of t ime 
r e s u l t e d i n a comple te d i s a p p e a r a n c e of t h e A-isoenzyme 
( F i g . l ) . Thus, d i e l d r i n t r e a t m e n t seemed t o a c c e l e r a t e t h e 
age -dependen t l o s s of t h e A-a l an ine -amino t r a n s f e r a s e i s o -
enzyme . 
P y r u v a t e k i n a s e isoenzyme a c t i v i t i e s 
The a c t i v i t y of t h e L-PK was lowered by d i e l d r i n t r e a t m e n t 
t h r o u g h o u t t h e whole o b s e r v a t i o n p e r i o d , p r o p o r t i o n a l t o t h e 
d i e t a r y d i e l d r i n c o n c e n t r a t i o n (Tab le I ) . An even more p r o -
nounced d e c r e a s e was seen i n l i v e r nodu le s when compared t o 
t h e non-nodu la r s u r r o u n d i n g t i s s u e of t h e d i e l d r i n - t r e a t e d 
l i v e r (Tab le I I ) . 
TABLE I - PYRUVATE KINASE ISOENZYME ACTIVITY IN THE LIVERS OF DIELDRIN TREATED CF-1 MICE 
PK act iv i ty (nM/mg soluble protein/min) 
Treatment 
1.5 
PK-
isoenzyme 
L 
K 
L 
K 
L 
K 
L 
K 
0 
64.7 + 
17.2 + 
124.6 + 
32.8 + 
190.0 + 
43.5 + 
195.8 + 
55.7 + 
8.9 
4.8 
19.9 
8.1 
25.3 
8.6 
8.8 
12,7 
1 
65.4 
17.2 
139.9 
39.0 
199.4 
44.9 
-
, 
+ 
+ 
+ 
+ 
+ 
+ 
Dieldrin dose 
15.3 
10.0 
19.8 
6.8 
29.5 
11.9 
5 
57.3 + 
19.9 + 
118,4 + 
43.9 + 
165.0 + 
62,1 + 
183.5 + 
68.2 + 
(PPm) 
2.4 
3.8 
21.5 
14.lb 
26. lb 
13.2C 
10.8a 
11.4a 
10 
44.6 
17.5 
106.5 
50.7 
144.8 
72.9 
161.1 
76.7 
17.1 C 
+ 6.1 
+ 24.4b 
• 6.0C 
+ 17.8C 
+ 8.6C 
+ 12.6C 
+ 3.9b 
n=5 in all cases, exept for 0 ppm at 3 and 6 months where n=10 
a; p<0.05, b: p<0.01, c: p<0.001 (significant difference between treatments and control). 
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The K-PK activity did not change for up to 1.5 months of 
treatment. After 3 months of treatment, however, dieldrin 
increased the K-PK activity. This effect appeared to be dose 
dependent (Table I). In liver nodules, the K-PK activity was 
found to be substantially higher, than in the non-nodular, 
dieldrin treated livers (Table II). 
TABLE II - PYRUVATE KINASE ISOENZYME ACTIVITY IN 
NORMAL LIVER TISSUE AND LIVER NODULES FROM CF-1 MICE 
TREATED WITH 10 PPM DIELDRIN FOR 14 MONTHS 
PK activity (nM pyruvate/mg soluble protein/min) 
Nodules " L-PK K-PK 
Small 155.8 +36.7 8 6 . 1 + 1 5 . 7 
Large 160.8 + 12.0 117.9 + 11.1 
None 181.2 +18.0 64.6+15.9 
n=4 in all cases 
small nodules : weight < 300 mg 
large nodules : weight > 500 mg 
The L:K-PK ratio did not significantly change in untreated 
control CF-1 mice throughout the entire observation period of 
14 months. However, the L:K-PK ratio was lowered dose-
dependently by dieldrin in the initial phases of treatment. 
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The duration of treatment had no additional effect upon the 
dieldrin-induced change in the L:K-PK ratio (Fig.2). 
In liver nodules a strong decrease in the L:K-PK ratio was 
observed. These findings suggest that the initial shift reflects 
an adaptation of the liver to increased functional demands 
imposed by dieldrin treatment. 
8 80H 
c 
'.£ 
1 
k-
>» 
û- 70 H 
àe 
60-
55 
0 1 5 10 SN LN 
ppm Dieldrin 
Figure 2 - Relative amount of L-pyruvate kinase, and standard 
deviation (vertical bars) in the livers of dieldrin-treated 
CF-1 mice, calculated from Tables I and II. 
SN, small nodules (weighing < 300 mg), 
LN, large nodules (weighing > 500 mg). 
Lactic dehydrogenase subunit composition 
In untreated control CF-1 mice an age-dependent decrease 
of M-LDH subunits was observed. Dieldrin resulted in a dose-
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dependent increase of M-LDH subunits in the initial phases of 
treatment. Thereafter, an age-dependent decrease of M-LDH 
subunits was observed similar to the one seen in untreated 
controls (Table III). It would thus appear that the initial 
shift reflects an adaptation of the liver to the dieldrin 
treatment in the same way as observed for PK-isoenzymes. 
TABLE III - THE PERCENTAGE OF THE M-LACTIC DEHYDROGENASE 
SUBUNITS IN THE LIVERS OF DIELDRIN TREATED CF-1 MICE 
% M-LDH 
Dieldrin Treatment time (months) 
dose (ppm) 
3 (n) 9 (n) 14 (n) 
0 67.0 + 5.7 (7) 65.3 + 2.7 (4) 61.6 + 6.9 (4) 
1 71.5 + 6.1 (4) 
5 73.9 + 4.4 (5)" 67.4 + 7.8 (4) 
10 78.3 + 4.0 (5)= 71.4 + 4.8 (4)t" 71.5 + 6.2 (3)-
10<* - - 7 8 . 5 + 1 . 5 ( 3 ) = 
n: animal number 
a: p < 0.05, b: p < 0.01, c: p < 0.001 (significant difference 
between treatments and control). 
d: liver nodules 
In nodular liver 'tissue the proportion of M-LDH subunits 
114 
was considerably increased over normal tissue. Such a shift 
in neoplastic liver tissue has been reported previously by 
several authors (Farron et al, 1972; Fischer et al., 1983). 
Histochemistry 
Changes in the glucose-6-phosphatase activity were used to 
identify preneoplastic lesion in CF-1 mouse liver, G-6-Pase 
being the best marker for foci in mouse liver. The amount of 
G-6-Pase deficient lesions was estimated using serial sec-
tions of frozen liver tissue. It was found that, after 14 
months of 10 ppm dieldrin treatment in normal liver tissue 
(i.e. dissected free from nodules) the volume occupied by 
preneoplastic lesions was: 2.9 + 1.6% (n=4). For all other 
treatment levels, the amount of G-6-Pase deficient foci was 
negligible, i.e. < 0.5%. 
DISCUSSION 
A possible mechanism by which dieldrin could operate as a 
liver tumour promotor might be the advancing of the biolo-
gical age of mouse liver. This concept has emerged from 
studies in which a dose dependent enhancement of the age-
related process of polyploidization was found in dieldrin 
treated CF-1 mice (van Ravenzwaay et al., 1987). Moreover, 
the duplication of genetic material without cellular division 
has been suggested to be a cause of ageing (Ohno and Yukifumi 
1978). 
The quantitation of isoenzyme activity offers a quick and 
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reproducible method to obtain insight into age-dependent 
changes in gene-expression. In the present hypothesis diel-
drin was expected to interfere with age-dependent physiolo-
gical mechanisms. Alternatively dieldrin could, in principle, 
exert its influence on isoenzyme activity by a direct allo-
sterical interference with the isoenzymes. Therefore all 
isoenzyme assays were first carried out in the presence of 
dieldrin. It was found that dieldrin at a concentration of 10 
ppm (the concentration actually found in the liver given an 
oral exposure of 10 ppm (Tennekes, 1979)) did not have a sig-
nificant influence on any of the isoenzymes investigated. 
Moreover, dieldrin is highly lipophilic and can therefore be 
assumed to be concentrated in the membrane compartment of the 
cell, whereas the isoenzymes assayed are all found in the 
cytoplasm. These findings contradict the possibility that 
dieldrin itself interferes directly with isoenzyme activity. 
Therefore it seems more likely that the functional commitment 
imposed on mouse liver by dieldrin may influence existing 
physiological mechanisms resulting in an altered isoenzyme 
composition. 
The expression of A-alanine amino transferase has been 
found to decrease with age in the studies of Kanungo et al. 
(1978) as well as in our studies. Dieldrin treatment resulted 
in a dose dependent decrease of A-alanine amino transferase 
expression (Fig.l). The results of the histochemical analysis 
of the livers showed that the amount of preneoplastic foci 
was so low that their presence cannot be expected to exert a 
significant influence on overall isoenzyme composition in 
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normal CF-1 mouse liver tissue. Thus, these findings are not 
in variance with the proposed hypothesis that dieldrin treat-
ment may advance the biological age of CF-i mouse liver. 
In contrast, dieldrin treatment results in a dose depen-
dent shift in the expression of lactic dehydrogenase and 
pyruvate kinase isoenzymes towards the fetal types, in the 
initial phases of treatment. The duration of the treatment 
was found to have no additional effect on isoenzyme compo-
sition. In the case of LHD the age dependent decrease of M-
subunits was the same in dieldrin treated groups and in 
untreated controls (Table III). The L:K-PK ratio did not 
change at all with age (Fig 2). The lack of any influence of 
the length of exposure time suggests that a "steady-state" 
situation is maintained. Thus, the initial shift induced by 
dieldrin would appear to be an adaptation of the liver to 
increased functional demands. 
A further shift towards fetal isoenzymes was observed in 
liver nodules. These findings are not in variance with the 
reported fetal character of (liver) tumours (Farron et al., 
1972). 
In conclusion, it would seem that dieldrin treatment can 
advance age-dependent changes in isoenzyme expression. It is 
conceivable that advancing the biological age of a mouse 
strain, prone to "spontaneous" age-related liver tumour for-
mation, may result in an enhancement of liver tumour develop-
ment in these mice. 
The paradox of advanced biological ageing and the 
induced shift towards fetal isoenzymes both resulting from 
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dieldrin treatment may be solved by a concept put forward by 
Jose Uriel (1976) : retrodifferentiation (the shift towards 
fetal isoenzymes) seems to be an alternative to the cell's 
risk of undergoing irreversible changes when their homeostatic 
barriers are surpassed (i.e. the adaptation of the liver to 
dieldrin in the initial phases of treatment ). The long-term 
effects of dieldrin treatment (advancing age-dependent 
processes), which occur in "steady-state" situations, would 
seem to be of a different nature. These long-term effects are 
more likely to be involved in the enhanced liver tumour 
formation in dieldrin treated CF-1 mice. 
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CHAPTER 2.5 
ACCELERATED NUCLEAR POLYPLOIDIZATION AND TUMOUR FORMATION IN THE 
LIVERS OF DIELDRIN TREATED CF-1 MICE 
Ben van Ravenswaay and Werner Kunz 
The German Cancer Research Centre, Institute of Biochemistry 
Im Neuenheimer Feld 280 D-6900 Heidelberg, FRG 
(Submitted to the British Journal of Cancer) 
ABSTRACT 
Nuclear polyploidization in the livers of CF-1 mice, exposed to 
dieldrin (0, 1, 5 and 10 ppm in the diet), was studied up to the 
median time to liver tumour development (ranging from 15 to 27 
months) in the respective treatment groups. In untreated controls 
nuclear polyploidization is characterized by a linear increase of 
octaploid nuclei with age. Approximately «4 months before tumour 
development a reduction in the tetraploid to diploid ratio is 
observed. Dieldrin treatment was found to enhance nuclear 
polyploidization in the initial phases of treatment, as expressed 
by a dose-dependent increase in octaploid nuclei. In "steady-state" 
situations all age dependent changes in the level of 
polyploidization found in controls were also found in dieldrin 
treated mice. However, these changes occurred at an increasingly 
earlier age with higher dieldrin treatment levels. The decrease in 
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the tetraploid .-diploid ratio always takes place a few months before 
tumour development. This change in the ploidy level may thus be 
related to the subsequent liver tumour formation. The liver tumours 
themselves appear to originate from a diploid stem line, and were 
found to increase their degree of polyploidization during growth, 
eventually developing aneuploid nuclei. A comparison of nuclear 
polyploidization and liver tumour formation in CF-1 mouse liver for 
the given dietary dieldrin concentrations showed that liver tumour 
formation was associated with a constant level of polyploidization. 
Since polyploidization is an age-depending process, these findings 
suggest that liver tumour formation is imminent at a constant 
biological age and that dieldrin may advance the biological age of 
CF-1 mouse liver. 
INTRODUCTION 
The CF-1 mouse strain is characterized by the development of "spon-
taneous" liver tumours when they reach an advanced age. Continuous 
treatment with microsomal enzyme inducers, such as drugs, food 
additives and pesticides, results in an induction of liver microso-
mal enzyme systems, liver enlargement and an increase in total liver 
DNA in the initial phases of treatment (1-3). Thereafter a "steady-
state" situation is maintained. The induced changes are reversible 
upon withdrawal and elimination of the compound and are not 
accompanied by evidence of liver damage. Thus, these changes are 
likely to be an adaptation of the liver to increased functional 
demands. However, exposure to microsomal enzyme inducers, such as 
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dieldrin has been shown to enhance liver tumour formation in 
these mice (4-6). 
Microsomal enzyme inducers are also known to enhance nuclear 
polyploidization in rodent liver (7,8). In a recent study (9) it 
was reported that nuclear polyploidization in livers of CF-1 mice 
increased proportionally to the dietary dieldrin concentration 
within a few weeks after the initiation of treatment. In "steady-
state" situations only an age-dependent increase in nuclear 
polyploidization was found, which exhibited an equal velocity in 
all treatment groups including controls. An estimation of the mean 
level of nuclear polyploidization (employing the linear regression 
of the data) at the median time to liver tumour development (= 50% 
incidence) revealed that this level should be the same across all 
groups. 
The objectives of the present study were to ascertain whether or 
not the degree of polyploidization at the median tumour induction 
period would be equal across all doses. In our previous report 
polyploidization was quantitated by the proportion of octaploid 
(8c) and 16c nuclei only. This study reports the age and dose 
dependent changes of the other ploidy classes, diploid (2c) and 
tetraploid (4c), as well as the 8c and 16c nuclei. Furthermore, the 
level of nuclear polyploidization in the dieldrin induced liver 
tumour was determined. The greatly reduced glucose-6-phosphatase 
(E.C. 3.1.3.9) enzyme activity in liver nodules was used to 
ascertain the presence of preneoplasic foci in sections of normal 
liver tissue. 
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MATERIALS AND METHODS 
Chemicals. The fluorochrome DAPI was obtained from Serva, 
Heidelberg, FRG. Glucose-6-phosphatase was obtained from 
Boehringer, Mannheim, FRG. All other chemicals were purchased from 
Sigma Chemical Co., Munich, FRG. 
Animals. CF-1 mice were kindly provided by Shell Research Ltd, 
Sittingbourne, Kent, UK. The colony was maintained under SPF 
conditions at Ivanovas GmbH, Kieslegg, FRG. Weanling female CF-1 
mice were supplied to the German Cancer Research Centre upon request. 
The animals were allocated to groups and acclimatised for 1 week. 
Dieldrin treatment commenced at «4-5 weeks of age. The animals, 
were exposed to 0, 1, 5 or 10 ppm dieldrin in a C-1000 diet (control 
and experimental diets were prepared by Altromin GmbH, Lage, FRG). 
Diet and water were given ad libitum. To determine polyploidization 
between 5 and 11 animals/group were killed at the indicated exposure 
time. 
Isolation of Liver Nuclei. Animals were weighed and killed by 
cervical dislocation in "steady-state" situations (i.e. not before 
8 weeks after the initiation of treatment). Livers were quickly 
excised, the gall-bladder was removed and the tissue was weighed. 
The livers were chilled in ice-cold 0.25 M Sucrose/TKM (0.05 M 
Tris-HCl, pH 7 4, 0.025 M KCl and 0.005 M MgClœ), for a few minutes. 
If tumours were present, livers were then dissected free from 
observed nodules and tissues were weighed. For both tissues one 
part was used to isolate nuclei, the other part was used for 
histochemical analysis. 
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Liver nuclei were isolated according to Blobel and Potter (10). 
Nuclear pellets were resuspended in 0.35 ml TKM buffer, and fixed 
by injection into tubes containing 12 nil absolute ethanol at -20 C". 
Flow Cytometry. DNA analysis was performed using 4'-6'-diamidino-2-
phenylindole dihydrochloride (DAPI) as the quantitative fluoro-
chrome (11). Flow cytometry was carried out as reported previously 
(9). In each case «40 000 nuclei were measured. The percentages of 
diploid and polyploid nuclei were corrected for doublets and 
higher aggregates of nuclei according to Beck (12). 
Histochemical Analysis. Serial sections of 10 urn were prepared at 
-15 C° on a cryostat microtome and used for the enzyme histochemi-
cal procedure. Glucose-6-phosphatase activity was demonstrated 
according to the method of Wachstein and Meisel (13). Three 
sections of each liver were projected (magnification x 45) and 
digitized using a manual optic picture analyser (Kontron, Digicon, 
Munich, FRG) and the proportion of G-6-Pase deficient 
preneoplastic foci was subsequently quantitated. 
RESULTS 
Nuclear Polyploidization in Non-Nodular Liver Tissue. In the liver 
of CF-1 mice three distinct ploidy classes could be found during 
the entire observation period: diploid, tetraploid and octaploid 
nuclei. Nuclei of an even higher ploidy level e.g. 16c were found 
in aged mice, their proportion remained low (<3.5%), however. 
Polyploidization in the livers of untreated control CF-1 mice was 
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found to be determined by two phenomena. Up until the age of 14 
months nuclear polyploidization was characterized by a slight 
decrease of the proportion of diploid (2c) and tetraploid (4c) 
nuclei. Between 14 and 25.5 months the proportion of 4c nuclei 
decreased at a higher velocity. Concomitantly, the proportion of 
2c nuclei did not decrease any further or even increased 
somewhat. The percentage of octaploid (Sc) nuclei was found to 
increase linearly with age during the entire experimental 
observation period (Fig. 1). 
Continuous feeding of dieldrin at dietary concentrations of 1, 5 
and 10 F'pm was found to enhance the proportion of 8c nuclei 
linearly with the treatment level in the initial phases of 
treatment, as reported previously (9). In these phases the 
percentages of 2c and 4c nuclei decreased slightly with increasing 
dieldrin dose. 
The percentage of Sc nuclei was found to increase proportionally 
with age, the velocity of this process being the same in all 
treatment groups including controls, until liver tumour formation 
(i.e. death). In untreated controls the experiment was terminated 
after 25.5 months (i.e. 4.5 months before the median time to liver 
tumour development in this group) because the number of mice 
surviving until 30 months was not expected to be high enough to 
determine polyploidization. Therefore no data for polyploidization 
were obtained at the median time to liver tumour development in 
untreated control CF-1 mice. 
In all treatment groups an age-dependent decrease of the 
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proportion of 2c and 4c nuclei was found, similar to the one 
observed in controls. Also similarly to controls, the loss of 4c 
nuclei increased in the later phases of life and continued to 
increase until liver tumour development. During these months the 
percentage of 2c nuclei was found to increase {Figs. 2-4). The 
induction of the change in the 4c:2c ratio appeared to be dose-
dependently advanced in time by the dietary dieldrin concentration. 
In controls the change in the 4c : 2c ratio was first observed after 
25.5 months, with a treatment of 1 ppm dieldrin after 21.5 months, 
with 5 ppm after 14 months and with 10 ppm after 9 months (Figs. 1-
4) . 
At the median time to liver tumour formation polyploidization 
was found to be approximately the same in all treatment groups 
(Table 1). 
Extrapolation of the linear regression of the percentage of 8c 
nuclei against time for untreated controls (experimental 
observation until 25.5 months) to the median time of tumour 
development in this group (30 months) gives an expected 8c 
proportion of 21.8 % . This value is in agreement with the ones 
obtained for dieldrin-treated CF-1 mice (Table 1), and emphasizes 
that liver tumour formation is associated with a constant level of 
polyploidization. 
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Fig. 1. Mean percentages and standard deviation of diploid [2c], 
tetraploid (4c) and octaploid (8c) liver nuclei in control CF-1 mice. 
160-
o 
C 
^ôO-
40-
30 
20 
10 
1 ppm dieidrin 
Animal number 
9 8 
r 
1 - . 
14 
— I — 
22 
- T 1 r -
24 26 28 
Time ( months ) 
10 
i 
12 
i 
16 
i 
18 
l 
20 
129 
Fig. 2. Mean percentage and standard deviation of diploid (2c), 
tetraploid (4c) and octaploid (8c) liver nuclei in CF-1 mice treted 
with 1 ppm in the diet. 
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liver nuclei in CF-1 mice treated with 5 ppm dieldrin in the diet 
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Fig. 4. Mean percentage and standard deviation of 2c, 4c.and 8c 
liver nuclei in CF-1 mice treated with 10 ppm dieldrin in the diet 
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Table 1. Nuclear polyploidization at the median time to liver 
tumour formation in CF-1 mice exposed to a dietary dieldrin 
concentration of 1, 5 and 10 ppm"" 
Dieldrin Dose Median Liver Tumour Percentage 
(ppm) Induction Period 
(months) 2c 4c Sc 
1 (5) 27.25 5 1 . 6 + 3 . 8 2 2 . 4 + 2 . 8 2 1 . 0 + 2 . 2 
5 (5) 21.5 5 4 . 6 + 3 . 5 2 3 . 6 + 3 . 0 2 1 . 2 + 2 . 0 
10 (6) 15.25 5 2 . 5 + 4 . 1 2 3 . 4 + 5 . 5 2 0 . 8 + 1 . 0 
Nuclear Polyploidization in Liver Nodules. Liver nodules, 
dissected free from the surrounding normal liver tissue were 
stained for glucose-6-phosphatase activity. G-6-Pase negative 
nodules (Fig. 5) were divided into three groups according to their 
'..•eight and were subsequently analysed for polyploidization. 
Liver nodules with a weight <300 mg contained mainly 2c nuclei. 
With increasing weight the proportion of 2c nuclei decreased and 
the proportion of 4c nuclei increased. In nodules weighing >500 mg 
even 8c nuclei were found (Table 2). In liver nodules weighing 
<500 mg no aneuploid nuclei could be detected. However, the large 
nodules (>500 mg) contained approximately 7% aneuploid nuclei 
(Table 2). Interestingly, all of these nodules contained a 
aneuploidy class of approximately 2.8c. Some of the nodules were 
found to have additional aneuploidy classes of 1.6c and 5.0c. 
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Fisure 5. Glucüse-6-phosphätase negative liver nodule. 
Quantitation of Preneoplastic Foci. Slices of non-nodular liver 
tissue were stained for glucose-6-phosphate activity to ascertain 
whether or not microscopic preneoplastic foci were present. If pre-
sent, the amount of G-6-Pase negative foci was quantitated. It was 
found that foci in non-nodular liver tissue could be detected only 
at the end of the dieldrin exposure time. The amount of G-6-Pase 
negative foci was highest in the 10 ppm treatment group after 14 
months of exposure: 2.9 + 1.6 % (n=4). After 21 months of 5 ppm 
dieldrin exposure the amount of foci was 1.32 + 0.31 % (n=4); 
in the i ppm group after 27.25 months, 2.00 + 0.82 % (n=4); and 
in untreated controls after 25.5 months, .0.65 + 0.35 % (n=4). In 
all other cases the amount of G-6-Pase deficient foci was 
negligible. 
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Table 2. Nuclear polyploidization (%) in glucose-6-phosphatase 
negative liver nodules taken from CF-1 mice treated with 5 and 10 
ppm dieldrin in the diet™ 
Ploidy Class Tumour Weight 
•- 300 mg (3) 300-500 mg (4) >500 mg (4) 
2c 82.3 + 3.1 (%) 65 . 1 + 9 . 1 40.3+16.5 
4c 1 5 . 5 + 4 . 8 3 2 . 3 + 6 . 8 4 0 . 5 + 1 6 . 4 
Sc 0.0 0.0 1 0 . 8 + 7 . 2 
aneuploidy 0.0 0.0 7.2 + 5.9to 
a: number of nodules used to determine nuclear polyploidzation 
is indicated in parentheses 
b: aneuploidy classes found were : 1.6c, 2.Sc, and 5.0c 
DISCUSSION 
The quantitation of glucose-6-phosphatase negative preneoplastic 
foci in non-nodular liver tissue showed that the volume occupied by 
these foci was very low (<2.9 % in all cases). Their presence thus 
cannot be expected to have a significant impact on the results of 
the determination of nuclear polyploidization in non-nodular liver 
The percentage of 8c nuclei in the liver of CF-1 mice was found to 
be dose-dependently enhanced during the initial phases of dieldrin 
treatment. In "steady-state" situations the percentage of Sc nuclei 
increases linearly with age. At the median time to liver tumour 
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development the mean value of 8c nuclei, for all treatment groups 
including controls, was 21. 3 + 0.53%. These findings confirm our 
previous extrapolations ("3) which were based on observations until 
14 months of treatment. In our earlier report (9) it was proposed 
that liver tumour formation was imminent at a constant biological 
age of mouse liver. Dieldrin may thus operate as a tumour promotor 
by advancing the biological age of the liver in a mouse strain 
prone to age-related "spontaneous" liver tumour formation. The 
results of this study further emphasize this concept. As shown in 
Figs. 1-4, the process of polyploidization (i.e. the kinetics of 
2c, 4c and 8c nuclei) observed in untreated controls can also be 
found in dieldrin treated CF-1 mice but at an increasingly earlier 
age with higher dietary dieldrin concentrations. The time-gaps 
created by dieldrin between the biological and chronological age of 
CF-1 mouse liver for both liver tumour formation (6) and nuclear 
polyploidization turned out to be virtually the same. The ob-
served quantitative relationship between the degree of nuclear 
polyploidization and liver tumour formation leads to the question 
as to whether or not a causal relationship between nuclear 
polyploidization and tumour formation exists. An interesting 
feature in the observed kinetics of nuclear polyploidization is the 
decrease in the 4c : 2c ratio. The onset of this decrease occurs 
approximately 4 months before the median time to liver tumour 
development in all treatment groups including controls. A decrease 
in the 4c : 2c ratio during carcinogenesis is not an entirely new 
observation. Neil et al. (14) have found that the administration of 
aflatoxin Bl resulted in a decrease of 4c nuclei. Styles et al. 
(15) have also reported a decrease in the 4c : 2c ratio when rats 
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were exposed to the liver carcinogen 3'-methyl-4-dimethylaminoazo-
benzene. Moreover, it has been reported that 4c nuclei bind more 
than twice the amount of carcinogen than 2c nuclei (16). It would 
appear that 4c nuclei are more sensitive than other ploidy classes. 
The fate of the disappearing 4c nuclei is not yet known, 
however, two mechanisms can be proposed and their implications for 
hepatocarcinogenesis discussed. 
1) Tetraploid cells could, assuming that they are more sensitive to 
toxicity than other ploidy classes, die when (cumulative) toxic 
stress goes beyond their homeostatic barriers. Since measurements 
were performed during "steady-state" situations, i.e. with no gross 
increase or decrease of liver weight, the necrotic 4c nuclei must 
be replaced by 2c nuclei (the kinetics of 8c nuclei are not 
affected by the change in the 4c : 2c ratio). The reduction of 4c 
nuclei ranges between 15%-20/'o of the total amount of liver nuclei. 
Since tetraploid nuclei and ceils are twice the size of diploid 
ones (17), two diploid cells have to divide to replace one 
tetraploid cell. Therefore, the observed decrease in the 4c : 2c 
ratio should result in a strong proliferative signal in the diploid 
population. By this mode of action the intrinsic neoplastic 
potential of CF-1 mouse liver may be activated resulting in liver 
tumour formation. 
2) A decrease in the 4c:2c ratio could also occur if the percentage 
of tetraploid cells were reduced by amitotic nuclear division as 
observed for polyploid rat liver nuclei (IS) and for rabbit 
trophoblasts (19). In such a case several mechanisms could explain 
the subsequent tumorigenesis. a: Spontaneous mutations may be 
duplicated by polyploidization resulting in a heterozygous 
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Situation -MMmm-. Nuclear division of such a tetraploid cell, 
would, by means of random segregation of chromosomes, result in 
the occurrence of some diploid -mm- cells, homozygous for the 
carcinogenic mutation, a concept which has been advanced previously 
(20,21). b: Since males, females and their offspring are all 
characterised equally by the development of "spontaneous" liver 
tumours (4,22) it could be suggested that the neoplastic factor is 
present in a homozygous form in all CF-1 mice. Since dieldrin has 
been shown to be devoid of any mutagenic potential (23,24) it would 
thus appear that the intrinsic neoplastic factor must be activated 
in order to induce liver tumours. An amitotic division of 
tetraploid cells could give rise to chromosomal rearrangements 
favourable for subsequent tumour formation. At least two mechanisms 
could account for the activation of the neoplastic factor. 
Translocation of this factor could enhance its expression in the 
same way as has been reported for the c-myc oncogene in human 
lymphomas (25,26). Events leading to an amplification of the 
neoplastic factor (e.g. unequal sister chromatid exchange between 
homologous chromosomes), could disturb the balance between 
expressors and suppressors, resulting in tumour development (27). 
c: By the same mode of action a factor repressing the expression 
of the neoplastic factor may be inactivated or diluted, with 
subsequent tumorigenesis. Impaired expression of a tumour 
suppressing gene has been demonstrated to be involved in tumour 
development in the case of human retinoblastomas (28) and Wilm's 
tumours (29). 
The results of the determination of nuclear polyploidization in 
liver nodules show an increasing occurrence of polyploid nuclei 
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with increasing weight (i.e. age) of nodules (Table 2 ) . Medvedev 
and Medvedeva (30) have also reported that nuclei with a high 
ploidy level were found only in the larger "spontaneous" 
hepatocarcir.omas of CBA mice. In this report it has been shown that 
in the largest liver nodules approximately 7% of all nuclei were 
aneuploid. Aneuploidy is generally regarded as a situation 
indicating malignancy. It has indeed been found that the 
"spontaneous" liver tumours of CF-1 mice do become malignant and 
metastasize, as shown in Fig. 6. The shift from 2c to 4c and Sc 
nuclei in liver nodules with increasing weight (Table 2) suggests 
that the origin of the liver nodules may be found in the diploid 
population. This would be in agreement with the proposed-mechanisms 
for the activation of the intrinsic neoplastic potential of CF-1 
mice, which ail implicate the diploid population as the source of 
CF-1 mouse liver tumours. 
Figure 6. Metastasis of a liver tumour in CF-1 mouse lung 
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CHAPTER 2.6 
POLYPLOIDIZATION AND ITS POSSIBLE ROLE IN HEPATOCARCINOGENESIS: 
STUDY WITH 3H-THYMIDINE-LABELLED NUCLEI IN DIELDRIN-INDUCED 
HEPATIC NUCLEAR POLYPLOIDIZATION 
Ben van Ravenzwaay1, Michael Stöhr2 and Werner Kunz1 
institute of Biochemistry, 2Institute of Experimental Pathology, 
The German Cancer Research Center, Im Neuenheimer Feld 280, 
D-6900 Heidelberg, FRG. 
(submitted to Carcinogenesis) 
Exposure to a variety of xenobiotic compounds has been shown to en-
hance liver tumour formation in mouse strains susceptible to "spontaneous" 
liver tumour formation (1-3). Moreover, these compounds have also been 
shown to promote the formation of rat liver tumours from lesions pre-
viously initiated by hepatocarcinogens (4-5). It has been suggested that 
these xenobiotics, which are inducers of microsomal enzyme activity, in-
crease the functional pressure on the liver and may thus facilitate the 
expression of its intrinsic neoplastic potential (1,6). Nuclear poly-
ploidization has also been shown to be related to the level of functional 
commitment (7-9). In our previous report we have demonstrated that liver 
tumour formation in CF-1 mice, exposed to various concentrations of 
dieldrin, is associated with a constant level of polyploidization (10), 
suggesting a relationship between polyploidization and liver tumour 
formation. Concerning the nature of this relationship we proposed that 
if the duplication of genetic material were to be followed by some 
(amitotic) nuclear divisions (and chromosomal redistributions), then 
heterozygous mutations could turn homozygous, a concept originally put 
forward by Kinsella and Radsman (13). In our earlier report (10) nuclear 
polyploidization in dieldrin-treated CF-1 mouse liver was determined for 
a period of 14 months. Recent findings demonstrated a decrease in the 143 
tetraploid-diploid ratio of hepatocyte nuclei approximately 4 months be-
fore tumour development in all treatment groups (van Ravenzwaay, unpub-
lished results). These findings may be associated with a carcinogenic 
mechanism (11), and they emphasized the possible role of amitotic 
nuclear divisions (12). 
The objectives of the present study were to ascertain whether 
amitotic nuclear divisions in hepatocytes could be detected. 
Eight-week-old, male, CF-1 mice (kindly provided by Shell Research 
Ltd, Sittingbourne, Kent, U.K.) were exposed to 0 or 10 ppm dieldrin 
in the C-1000 diet (prepared by Altromin GmbH, Lage, FRG). Five hours 
after the initiation of the experiment (i.e. 2 p.m.), all mice of both 
treatment groups received a subcutaneous injection of 3H-thymidine 
(Amersham) with an activity of 5 yiCi. Three days later this procedure 
was repeated. Four weeks after initiation of the experiment, five animals 
of the control and 10 ppm dieldrin groups were killed by cervical dis-
location, and the remaining mice of the 10 ppm treatment group were put 
on a control diet thereafter. Three weeks later these animals were also 
killed. Liver nuclei were isolated as described by Blobel and Potter 
(14). Nuclear pellets were resuspended in 0.35 ml TKM [0.05 M Tris-HCl, 
pH 7.4 (20°C), 0.025 M KCl and 0.005 M MgCl2] buffer and fixed. 
Determination of nuclear polyploidization and sorting were carried 
out by double staining with DAPI (4'-6-diamidino-2-phenylindole dihydro-
chloride) and S R J Q I (sulphorhodamine) using the HEIFAS cell sorter. This 
system has been described elsewhere (15). For nuclear polyploidization 
determination 40 000 nuclei were measured; the determination of 3H-
thymidine activity was done with no less than 350 000 nuclei/animal in 
each ploidy class. 
The 3H-thymidine activity (expressed in CPM/100 000 nuclei for each 
ploidy class) in untreated controls four weeks after the 3H-thymidine 
application did not differ among the three ploidy classes, the activity 
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being somewhat lower in 8c groups. Four weeks' exposure to 10 ppm 
dieldrin resulted in an increase in relative liver weight (+ 38%). This 
increase was found to be associated with polyploidization, resulting in 
an augmentation of the proportion of 8c nuclei, and a smaller one of the 
4c nuclei. The 3H-thymidine activity in the 10 ppm treatment group had 
increased slightly in the 2c group and remained virtually constant in 
the 4c group. In contrast, there was a profound increase of 3H-thymidine 
activity in the 8c group (+ 42%). These results suggest that DNA syn-
thesis, associated with dieldrin-induced liver enlargement, can be 
attributed to the increased formation of 8c nuclei in hepatocytes. 
Table 1. 3H-thymidine activity and percentage of nuclear polyploidization 
for each ploidy class in dieldrin-treated CF-1 mouse liver 
0 ppm (4 weeks) 10 ppm (4 weeks) "cessation" (3 weeks) 
2c 
3H 
4c 
3H 
8c 
3H 
RLW 
35.7 
65.9 
41.8 
70.1 
13.7 
58.8 
5.04 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
2.5% 
10 .5 a 
3.1% 
13.6 
2.9% 
10.9 
0.26 
32.3 
70.5 
43.2 
69.1 
19.2 
83.4 
6.93 
+ 
+ 
± 
+ 
+ 
+ 
+ 
3.2% 
10.2 
4.1% 
18.7 
1.7% 
13.1 
0.35 
40.8 
82.9 
35.8 
56.6 
15.9 
58.8 
5.28 
± 2.3% 
± 8.9 
± 1.6% 
± 11.5 
± 2.3% 
± 7.4 
± 0.29 
a: activity is expressed as CPM per 100 000 nuclei per ploidy class 
n = 5; RLW = relative liver weight 
Three weeks after cessation of treatment, relative liver weight had 
decreased to near control value. Dieldrin-induced polyploidization was 
also found to be reversible after discontinuation of treatment. The pro-
portion of 8c nuclei had decreased but was still somewhat higher than 
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in untreated controls. However, the proportion of 8c nuclei in untreated 
controls was determined three weeks before the one in the "cessation" 
group. Since the percentage of 8c nuclei in CF-1 mice increases propor-
tionally with time (10), the actual difference would, in reality, be 
smaller. The proportion of 4c nuclei was also found to be decreased; in 
this case the mean value of the "cessation" group was lower than in un-
treated controls. In contrast with the 4c and 8c nuclei, the proportion 
of 2c nuclei had increased (+ 26%) to a level higher than in untreated 
controls. 
The 3H-thymidine activity in the 8c group had returned to control 
value three weeks after cessation of treatment. In the 4c group, activity 
also declined. In comparison, the activity in the 2c groups was found to 
be increased after a three-week period of control diet feeding. 
The results of the present study demonstrate the reversibility of 
dieldrin-induced liver enlargement (as expressed in terms of relative 
liver weight) and nuclear polyploidization. The expected reversibility 
of both dieldrin-induced liver enlargement (1,2) and nuclear poly-
ploidization (van Ravenzwaay, unpublished observations) were important 
features in the rationale for experimentation. The induction of liver 
enlargement and nuclear polyploidization by dieldrin were expected to 
result in increased 3H-thymidine activity in the 8c group. This can be 
demonstrated even more clearly by calculating the average 3H-thymidine 
activity per 100 000 nuclei, as related to liver weight. In untreated 
controls average 3H-thymidine activity was 60.9 cpm; after 4 weeks of 
10 ppm dieldrin in the diet the calculated activity was 101.8 cpm. Since 
3H-thymidine was applied in two "pulses" at the beginning of the experi-
ment, no free 3H-thymidine was to be expected after 4 weeks of treatment. 
Thus, if the reversibility of liver enlargement and nuclear polyploidi-
zation were brought about by (controlled) cell death alone, only a de-
crease in the specific 3H-thymidine activity in these polyploid nuclei 
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is to be expected. If, however, some amitotic nuclear divisions of 
higher polyploid nuclei occurred during the regression phase, an in-
crease in specific 3H-thymidine activity in the lower ploidy (2c or 4c) 
groups should be detectable. 
The increased 3H-thymidine activity in the Zc groups (Table I) 
suggests that the reversibility of nuclear polyploidization can partly 
be attributed to the occurrence of amitotic nuclear divisions. It is 
interesting to note that the increased levels of 3H-thymidine activity 
found in the 8c group after four weeks of dieldrin treatment returned to 
control values three weeks after cessation of treatment. These findings 
suggest a "memory-effect" in the reversibility of nuclear polyploidiza-
tion, i.e. the 8c nuclei formed during the adaptation of the liver to 
dieldrin exposures are the ones that disappear during regression. The 
inference can be made that the recessive oncogenic potential of CF-1 
mouse liver is activated by a genetic mechanism. 
Acknowledgements 
The authors gratefully acknowledge the skilled technical assistance 
of Mr. Wolfgang Hien, Mr. Rolf Schmitt and Ms. Alison Fisher. 
147 
References 
1. Wright, A.S., Potter, D., Wooder, M.F., Donninger, C. and Greenland, 
R.D. (1972) The effects of dieldrin on subcellular structure and 
function of mammalian liver cells. Food Cosmet. Toxicol., 10, 311-332. 
2. Wright, A.S., Akintonwa, D.A.A. and Wooder, M.F. (1977) Studies on the 
interactions of dieldrin with mammalian liver cells at the subcellular 
level. Ecotoxicol. Environ. Saf., 1, 7-16. 
3. Tennekes, H.A., Wright, A.S., Dix, K.M. and Koeman, J.H. (1981) Effects 
of dieldrin, diet and bedding on enzyme function and tumour incidence 
in livers of male CF-1 mice. Cancer Res., 41, 3615-3620. 
4. Peraino, C , Fry, R.J.M., Stattfeldt, E. and Christopher, J.P. (1975) 
Comparative enhancing effects of phénobarbital, amobarbital, dipheyl-
hydantoin, and dichlorodiphenyltrichloroethane on 2-acetylaminofluorene-
induced hepatic tumorgenesis in the rat. Cancer Res., 35, 2884-2890. 
5. Peraino, C , Fry, R.J.M., Stattfeldt, E. and Christopher, J.P. (1977) 
Enhancing effects of phenobarbitone and butylated hydroxytoluene on 
2-acetylaminofluorene-induced hepatic tumorigenesis in the rat. Food 
Cosmet. Toxicol., 15, 93-96. 
6. Peraino, C , Fry, R.J.M., Stattfeldt, E. and Christopher, J.P. (1973) 
Enhancement of spontaneous hepatic tumourigenesis in C3H mice by 
dietary phénobarbital. J. Natl. Cancer Inst., 51, 1349-1350. 
7. Böhm, N. and Noltemeyer, N. (1981) Excessive reversible phénobarbital 
induced nuclear DNA polyploidisation in the growing mouse liver. 
Histochemistry, 72, 63-74. 
8. Schulte-Hermann, R. (1979) Adaptive growth induced by xenobiotic com-
pounds: its nature and mechanism. Arch. Toxicol. Suppl., 2, 113-124. 
9. Schulte-Hermann, R. (1974) Induction of liver growth by xenobiotic com-
pounds and other stimuli. Crit. Rev. Toxicol., 3, 97-158. 
10. Van Ravenzwaay, B., Tennekes, H., Stöhr, M. and Kunz, W. (1987) The 
kinetics of nuclear polyploidization and tumour formation in livers 
of CF-1 mice exposed to dieldrin. Carcinogenesis, 8, 265-269. 
11. Styles, J.A., Kelly, M. and Elcombe, C R . (1987) A cytological com-
parison between regeneration, hyperplasia and early neoplasia in the 
rat liver. Carcinogenesis, 8, 391-399. 
12. Doerder, F.P. and Diblasi, S.L. (1984) Recombination and assortment in 
the macronucleus of Tetrahymena thermophila: a theoretical study by 
computer simulation. Genetics, 108, 1035-1045. 
13. Kinsella, A.R. and Radman, M. (1978) Tumor promoter induces sister 
148 
chromatid exchanges: relevance to mechanisms of carcinogenesis. Proc. 
Natl. Acad. Sei. USA, 75, 6149-6153. 
14. Blobel, G. and Van Potter, R. (1966) Nuclei from rat liver: isolation 
method that combines purity with high yield. Science, 1541, 1662-1665. 
15. Stöhr, M. and Goerttler, K. (1979) The Heidelberg flow analyzer and 
sorter (HEIFAS) approach on the prescreening of uterine cancer. J. 
Histochem. Cytochem., 27, 564-566. 
149 
3 DISCUSSION 
The apparent paradox between thB revers ib i l i t y of dieldrin-induced 
changes in the l i vers of CF-1 mice ( l iver enlargement, microsomal enzyme 
induction and p ro l i fe ra t ion of the smooth endoplasmic reticulum) and the 
i r revers ib i l i t y of dieldr in enhanced l iver tumour formation may be 
considered as the main problem on which the studies presented in this 
thesis were focused. The tumorigenic e f f e c t s of microsomal enzyme 
inducers, such as dieldrin. can be explained by assuming that: 
a) dieldrin possesses a weak carcinogenic activity itself, or. 
b) dieldrin promotes the expression of an intrinsic neoplastic 
factor in CF-1 mouse liver. 
In this thesis i t is demonst ra ted that the dose-response charac ter is t i cs 
of dieldrin enhanced liver tumour formation can be expressed as: 
(do + &x) x t = constant (1) 
where do = the background dose equivalent for the induction of 
"spontaneous" l iver tumours in control CF-1 mice, i x = the actual dieldrin 
dose (ppm in the diet) and t = the median tumour induction period in CF-1 
mice t r e a t e d at a dieldr in level &x. This relat ionship is a Druckrey 
equation, with a re in forcement fac tor n=1. Since all chemical carcinogens 
have been shown to exhibi t dose-response relat ionships where n > 1 . this 
finding suggests that dieldrin cannot be considered as a weak carcinogen 
but e x e r t s i ts tumorigenic action by enhancing a p re-ex is t ing oncogenic 
fac tor (i.e. tumour promotion). Druckrey and Kiipfmiil ler (1949) have 
elucidated that a re in forcement fac to r n > 1 is associated with i r r e v e r s i -
bil i ty of recep to r binding and i r revers ib i l i t y of the e f f e c t of r ecep to r 
binding. A dose-response relat ionship where n = 1. such as the l iver 
tumour enhancing e f f e c t of dieldr in. is associated with ei ther i r r e v e r s i -
bi l i ty of recep to r binding or v/ith i r reve rs ib i l i t y of the e f f e c t of 
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receptor binding. There is evidence to indicate that the numeric value of 
the reinforcement fac to r (n) parallels the init iat ing capacity of the 
carcinogen (Schwarz e t a l . . 1984). Since dieldrin and i ts metabolites have 
been shown to be devoid of any genotoxic potent ial (Dean and Ooak, 1975; 
Bidwell e t al . . 1975). the observed value of n (=1) in the dieldrin study 
suggests that dieldrin binding to i ts recep to rs is reve rs ib le , whereas the 
e f f e c t of the recep to r binding on the neoplastic process is i r revers ib le . 
This inference is fu r ther confirmed by the complete revers ib i l i t y of 
dieldrin-induced subcellular changes (Chapter 3.2). 
Moreover, i t is demonstrated that the l iver tumour-enhancing e f f e c t s of 
(limited) t reatment with dieldrin followed by a t reatment f r e e per iod, and 
a t reatment f r e e period fol lowed by dieldrin application are consistent 
with equation (1). These findings indicate that: 
1) Liver tumour formation is associated with a constant total 
tumorigenic dose. 
2) There is no evidence for a threshold level. 
3) The ef fects of dieldrin on tumour formation are essentially 
irreversible and cumulative regardless of the time schedule of 
application. 
The fac t that even limited exposures of CF-1 mice to dieldrin lead to an 
increased l iver tumour r isk clearly cont rasts with the experimental 
observat ions obtained with skin tumour promotors. In a classical two-
stage model experiment using 2-acetylaminofluorene as the ini t iator of 
hepatocarcinogenesis and phénobarbital as the promotor. Peraino et al. 
(1977) also found evidence fo r the i r revers ib i l i t y of l iver tumour 
promotion. Pro-gress ive increases in the duration of phénobarbital 
t reatment shortened the tumour-induction periods and increased overal l 
tumour incidence levels. These resu l ts demonstrate that l iver tumour 
promotion may not be regarded as a reversible process. 
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These consideration are cr i t ical ly important in the assessment of the 
health e f f e c t s associated with human exposure to tumour promoting agents. 
Moreover. the lack of evidence for a threshold level of dieldrin mediated 
l iver tumour promotion fu r ther emphasizes the need for a re-evaluat ion of 
the health policy and r isks associated with l iver tumour promoters. In 
this contex t i t is important to note that the e f f e c t s of a l iver tumour 
promoter v/il! be more severe in populations exposed to high levels of 
in i t iators of hepatocarci-nogenesis. These populations may be found, for 
example, in the developing countr ies, where exposure to af latoxin B1 and 
chronic hepat i t is B (both in i t iators of hepatocarcinogenesis) a f f ec t the 
health of a large proportion of the population. 
The tumour-enhancing e f f e c t s of microsomal enzyme inducers. such as 
dieldrin. have been demonstrated not to be associated with any genotoxic 
action. The induction of l iver enlargement and microsomal enzyme systems 
suggests that dieldrin mediates i ts action by increasing the functional 
pressure on hepatocytes. Although there may be more than one recep to r for 
dieldrin i t can be demonstrated by the use of speci f ic P-450 isoenzyme 
antibodies (Fig. 1) that dieldrin mainly induces the P-450 d isoenzyme 
(van Ravenzwaay. unpublished results). 
The resul ts of the immuno-histochemal staining of l iver sect ions from CF-1 
mice exposed to 10 ppm dieldrin in the d ie t , suggest that dieldrin induces 
isoenzymes of the isosafrole type (see Table IV. Chapter 2.4.1). 
The tumour enhancing e f f e c t s of increased functional commitment in 
hepatocytes have gained fu r the r support f rom experiments conducted by Rehm 
et al. (1985). In their experiment per formed with NMFtl mice i t was 
observed that food res t r i c t i on , which reduces the functional commitment in 
hepatocytes, delayed the development of (spontaneous) tumours, but had no 
influence on overall tumour incidence. 
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V. 
P-450 b Control P-450 b 10 ppm dieldrin 
P-450 c Control P-450 c 10 ppm dieldrin 
P-450 d Control 
•*irî*ï 
P-450 d 10 ppm dieldrin 
^ • ^ 
P-460 f Control 
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P-450 f 10 ppm dieldrin 
Figure 1. 
Imnunohistochemical 
staining of 
different P-450 
isoenzymes in 
control and 10 ppm 
dieldrin treated 
CF-1 mouse liver 
A similar relationship between the level of functional pressure and 
nuclear polyploidization has been observed: induction of microsomal 
enzymes with phénobarbital enhances polyploidization (Böhm and Noltemeyer. 
1981). whereas food res t r i c t i on decreases the level of polyploidization 
(Enesco and Samborsky, 1983). The resul ts of the determination of nuclear 
polyploidization in the l ivers of CF-1 mice presented in this thes is , 
demonstrate that nuclear polyploidization. as expressed by the proport ion 
of octaploid (8c) nuclei. increases linearly with age. In addition. a 
dose-dependent enhancement of polyploidization was observed within 1.85 
months a f t e r commencement of dieldrin t rea tment . Most importantly i t was 
established that l iver tumour formation was associated with a constant 
degree of polyploidization for all t rea tment groups. including contro ls . 
On the premiss that polyploidization r e f l e c t s the ageing p rocess , i t may 
be concluded that dieldrin advances the biological age of CF-1 mouse 
l iver . It is conceivable that the increased functional pressure e x e r t e d by 
dieldrin on hepatocytes may accelerate the ageing process. 
The influence of dieldrin on the expression of isoenzymes in the l iver can 
be divided into two components. During the initial phases of t reatment a 
shi f t towards fe ta l types of pyruvate kinase and lact ic dehydrogenase was 
observed. This shi f t was demonstrated to be revers ib le and may be regarded 
as an adaptation of the l iver to dieldrin exposure. In con t ras t , i t was 
observed that dieldrin dose-dependently advances the age dependent sh i f t 
in alanine amino t rans fe rase in " s teady -s ta te " si tuat ions. These findings 
emphasizes the importance of accelerated biological ageing as a mechanism 
in dieldrin-mediated liver tumour formation. 
Further studies on the ro le of nuclear polyploidization on hepa-
£ocarcinogenesis in CF-1 mice revea led a marked decrease in the te t rap lo id 
(4c) diploid (2c) ra t i o , approximately 4 months be fore the median l iver 
tumour induction per iod, in all t reatment groups including contro ls . The 
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observat ion that the decrease in the 4c:2c ra t io which occur red in all 
t reatment groups a few months be fore l iver tumour format ion, and the fac t 
that such a decrease has previously been found to be associated with 
hepatocarcino-genesis (Styles et al . . 1985) suggested a possible r e l a -
tionship between this event and the subsequent l iver tumour formation. Two 
mechanisms are proposed to account for such a relationship: 
1) A reduct ion in the 4c:2c ra t io could resu l t from an increased turnover 
of te t rap lo id cel ls. Since l iver weight has been observed not to change 
during the ent i re exper iment, the lost te t rap lo id cells are likely to 
be replaced by diploid ones, resul t ing in a p ro l i fe ra t i ve stimulus 
on this cell population. 
2) Amitotic division of te t rap lo id nuclei would also resul t in a reduct ion 
of the 4c:2c ra t io without a change in l iver weight. Chromosomal r e -
arrangements during this event could turn heterozygous mutations homo-
zygous. 
Both hypotheses imply that the diploid population is the origin of the 
tumour. The resul ts from the determination of polypioidization in l iver 
tumours confirmed that these tumour or iginate from a diploid population. 
An ar t i f i c ia l reduct ion of the 4c:2c ra t io (induced by disconti-nuation of 
dieldrin t rea tment ) per formed with mice previously labelled with 3 H-
thymidine resu l ted in a sl ight increase of labelled diploid nuclei 
suggest ing that some amitotic divisions had occur red. In terest ing ly , the 
increased levels of H-thymidine in polyploid nuclei observed during 
dieldrin t reatment (indicating DNA synthesis for polypioidization) had 
re tu rned to control leve l . 3 weeks a f t e r discontinuation of t reatment . 
These findings suggest that the revers ib i l i t y of l iver enlargement (and 
polypioidization) may be a t t r ibu ted to the elimination of the excess 
polyploid cells induced during l iver enlargement. This "memory" e f f e c t 
g rea t ly increases the chance that heterozygous mutations. duplicated 
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during polyploidization. will tu rn homozygous as a resul t of amitotic 
divisions. The i r revers ib le enhancement of l iver tumour format ion, even 
a f te r a ve ry short exposure to dieldrin. also seems to favour a genetic 
mechanism. However. that chronic and limited exposure of CF-1 mice to 
dieldrin enhances l iver tumour formation following c t kinetics suggests a 
mechanism involving the cumulative e f f e c t s of dieldrin exposure, which are 
associated with the accelerated expression of the intr insic neoplastic 
potential in CF-1 mouse liver. 
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4. Summary 
A variety of xenobiotic compounds is known to induce characteristic 
changes in the livers of laboratory animals. These changes include en-
largement of the liver, usually as a result of cell enlargement (hyper-
trophy) or increased cell replication (hyperplasia), induction of drug-
metabolizing enzymes and proliferation of the smooth endoplasmic reti-
culum (SER). Such changes are usually not accompanied by evidence of 
liver damage and thus are reversible upon withdrawal and elimination of 
the compound. Consequently, most authors regard this phenomenon as an 
adaptive response of the organ to increased functional demands. 
However, chronic exposure of various strains of mice to dieldrin, 
phenobarbitone, DDT and the a-, (5- and v-stereoisomers of hexachloro-
cyclohexane (HCH, also known as benzenehexachloride, BHC) may lead to 
the development of liver tumours. 
The tumorigenic effects of microsomal enzyme inducers in mice may re-
sult from (a) a weak carcinogenic action of the xenobiotics themselves 
or (b) an enhancing (promoting) action of xenobiotics on a pre-existing 
oncogenic factor in mouse liver. The first objective of this study was 
to discriminate between these two possible types. 
Druckrey and his associates have established both theoretically and 
experimentally the dose-response characteristics of chemical carcino-
gens: 
D«Tn = constant (1) 
where D = daily dose, T = the median tumour induction period and n = an 
exponent, always > 1 . 
Since the mechanisms by which enhancers or promotors of carcino-
genesis operate is quite different from the one used by carcinogens, it 
is be conceivable that promotors also exhibit different dose-response 
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characteristics. 
The dose-response characteristics of dieldrin-mediated enhancement 
of liver tumour formation in CF-1 mice were analysed, using existing 
tumour data from chronic feeding studies at six exposure levels of 
dieldrin (a model compound for microsomal enzyme induction). It was 
found that the dose-response relationship can be expressed as: 
(d0 + 5x)-t = constant (2) 
where d0 stands for the background dose equivalent required for the in-
duction of spontaneous liver tumours, 6x represents the actual dieldrin 
dose (ppm in the diet) and t the median tumour induction period in the 
respective treatment groups. It was also established that the dose-
response characteristics of limited dieldrin exposures and those of de-
layed exposure were consistent with equation (2), which is a Druckrey 
relation where n = 1. 
From these findings it is concluded that dieldrin interacts rever-
sibly with its receptors, resulting in an acceleration of tumour forma-
tion (which is essentially irreversible); dieldrin may thus be regarded 
as a tumour promotor. The validity of equation (2) for both chronic and 
limited dieldrin exposure indicates that (a) the velocity of liver 
tumour development is proportional to the daily dose level (Sx), (b) the 
total tumorigenic dose is constant across all doses, (c) the effects of 
dieldrin on the neoplastic process in mouse liver are essentially irre-
versible and cumulative, and (d) there is no evidence for a threshold 
level. 
Tumour formation is a dose- and time-dependent process. The induction 
of liver enlargement, microsomal enzyme systems and proliferation of the 
smooth endoplasmic reticulum by dieldrin are only dose-dependent. In con-
trast, polyploidization is dose- and time-dependent. To establish a 
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possible link between microsomal enzyme induction, nuclear polyploidi-
zation and liver tumour formation, nuclear polyploidization in livers of 
CF-1 mice was studied at five different dieldrin dose levels from 1.85 
months up to tumour development. Nuclear polyploidization, expressed in 
the proportion of octaploid (8c) nuclei, was found to be characterized 
by a linear increase with age in untreated control CF-1 mice. Dieldrin 
treatment induced a dose-dependent increase in the proportion of 8c-
nuclei in the initial phases of treatment. In "steady-state" situations 
nuclear polyploidization (as expressed by the percentage of 8c-nuclei) 
was maintained on a dose-dependent, higher level, and the percentage was 
was observed to increase with age, the velocity of which was the same as 
in untreated controls. Tumour formation was found to be associated with 
a constant degree of nuclear polyploidization in all treatment groups 
Including controls. The observed quantitative link between nuclear poly-
ploidization and tumour formation leads to the question whether or not a 
causal relationship between the two exists. Assuming that polyploidi-
zation reflects the ageing process, the data suggest that liver tumour 
formation is imminent at a constant biological age and that dieldrin 
could operate by advancing the biological age of CF-1 mouse liver. 
Further support for this hypothesis was obtained from the determi-
nation of cytoplasmic alanine amino transferase (AAT) isoenzymes. The ex-
pression of the isoenzyme decreases with age in untreated control CF-1 
mice. Dieldrin treatment was found to enhance (accelerate) this process 
in a dose-dependent manner. 
Although the nature of the development of "spontaneous" liver tumours 
in CF-1 mice remains unknown, the decrease in the tetraploid(4c)-diplo1d 
(2c) ratio of liver nuclei, observed in the study of polyploidization, 
may be related to tumour formation. The decrease was observed in all 
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treatment groups, including controls, and its onset was dose-dependently 
advanced by dieldrin treatment, occurring approximately 4 months before 
the median liver tumour induction period in all cases. Two mechanisms 
are proposed that may explain the tumorigenic features of a decrease in 
the 4c-2c ratio. 
1. Tetraploid cells could be more sensitive to accumulative toxic stress. 
Thus, their turnover may be increased. To replace one tetraploid cell 
a diploid cell has to divide twice; the loss of tetraploid cells 
would therefore result in a proliferative response of the diploid 
population (resulting tumour formation). 
2. A reduction in the 4c-2c ratio could be induced by the occurrence of 
amitotic nuclear divisions in the tetraploid cells. Evidence for this 
possibility was obtained from experiments with 3H-thymidine-labelled 
nuclei. Amitotic nuclear divisions could give rise to chromosomal re-
arrangements, resulting in the expression of the intrinsic neoplastic 
potential of CF-1 mouse liver. 
Both hypotheses imply that the diploid population is the source of liver 
tumours. The determination of nuclear polyploidization in liver tumours 
confirmed that these tumours originate from the diploid liver cell popu-
lation. 
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5 SAMENVATTING 
Vele lichaamsvreemde stoffen zijn 1n staat karakteristieke veranderingen te 
induceren in de levers van proefdieren. Deze veranderingen zijn in het al-
gemeen als volgt samen te vatten: leververgroting als gevolg van een kombi-
natie van cel vergroting (hypertrophie) en cel vermeerdering (hyperplasie), 
inductie van microsomale enzymen voor de biotransfomatie van lichaamsvreemde 
stoffen, en proliferatie van het gladde endoplasmatische reticulum. 
Gewoonlijk hebben deze veranderingen geen lever beschadeging tot gevolg en 
zijn reversibel na stopzetting van de behandeling. Deze veranderingen worden 
daarom door velen als een aanpassing van de lever aan verhoogde functionele 
belastingen beschouwd. Chronische behandeling van muizen met verschillende 
lichaamsvreemde stoffen zoals DDT, dieldrin, phénobarbital en een aantal 
hexachloorcyclohexaan (HCH) isomeren, kunnen echter de ontwikkeling van 
lever-tumoren tot gevolg hebben. 
De kankerverwekkende eigenschappen van microsomale enzym inductoren kunnen 
het gevolg zijn van: 
1) een zwak carcinogeen effekt van de lichaamsvreemde stof zelf, of, 
2) een versterkend effekt van de lichaamsvreemde stof op een reeds voorhande 
zijnd oncogeen potentiaal, waardoor dit tot expressie komt. 
Het eerste doel van het in dit proefschrift beschreven onderzoek was een mo-
gelijkheid te vinden om te onderscheiden tussen de hierboven genoemde wer-
kings typen. Druckrey en zijn medewerkers toonden, meer dan 25 jaar geleden, 
aan dat de dosis-tijd-werkingsrelaties van chemische carcinogenen beschreven 
kunnen worden door: 
D«Tn = constant (1) 
waarin D = dagelijkse dosis, T = de gemiddelde latentie tijd voor tumor ont-
162 
wikkeling, en n = een exponent, altijd > 1 . De resultaten van vele experi-
menten hebben de validiteit van deze formule bevestigd. Aangezien het 
werkingsmechanisme van versterkers of promotoren van het carcinogene proces 
verschilt met de werking van volledige carcinogenen, 1s het waarschijnlijk 
dat promotoren een andere dosis-werkingsrelatie zullen vertonen. 
De dosis-werkingsrelatie van de door dieldrin (een typische microsomale en-
zym inductor) veroorzaakte leverkanker ontwikkeling in CF-1 muizen, kan wis-
kundig als volgt beschreven worden: 
(d0 + 6x)'t = constant (2) 
waarin d0 = de dosis equivalenten (uitgedrukt in ppm dieldrin 1n de voeding) 
die het ontstaan van "spontane" levertumoren in de controle groepen moeten 
verklaren, 6X = de werkelijke dieldrin dosis (ppm 1n de voeding) en t = de 
gemiddelde latentie tijd voor tumor ontwikkeling in de verschillende behan-
del ings groepen. 
Bovendien bleek dat zowel de dosis-werkingsrelatie voor een beperkte (niet 
chronische) dieldrin behandeling als ook die voor een dieldrin behandeling 
na een behandelings vrije periode (60 weken) in overeenstemming waren met 
vergelijking (2). Deze vergelijking is een Druckrey relatie (zie vgl. 1), 
waarbij de exponent n = 1 (bij carcinogenen: n altijd >•!). 
Uit deze resultaten kan geconcludeerd worden dat dieldrin een reversibele 
interactie aangaat met cellulaire bestanddelen, waardoor het tumorigene 
proces versneld wordt (een versnelling van de carcinogenese kan niet anders 
dan irreversibel zijn). Dientengevolge kan dieldrin als een tumor promotor 
beschouwd worden. 
Uit vergelijking (2) kan worden afgeleid dat, bij behandeling van CF-1 mui-
zen met dieldrin: 
1) De snelheid van leverkanker ontwikkeling proportioneel is aan de som van 
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de dagelijkse dleldrln dosis en de dieldrin equivalenten voor de lever-
tumor ontwikkeling in de controle groepen. 
2) De totale tumorigen dosis, gegeven tot het optreden van lever kanker, is 
constant voor alle behandelings groepen 
3) De gevolgen van dieldrin behandeling op de tumor ontwikkeling zijn irre-
versibel en cumulatief. 
4) Er zijn geen aanwijzingen gevonden die op het bestaan van een drempel-
waarde duiden. 
Kanker ontwikkeling is een dosis- en tijds-afhankelijk proces: De Inductie 
van lever vergroting, de proliferatie van het gladde endoplasmatische reti-
culum en de inductie van microsomal e enzymen, zijn allen dosis afhankelijk. 
Polyploidisering echter, is een proces dat, net als kanker ontwikkeling, zo-
wel van de dosis als ook van de tijd afhankelijk is. 
Om een mogelijk oorzakelijk verband tussen microsomale enzym inductie — 
polyploidisering ~ leverkanker vast te kunnen stellen werd de polyploldi-
serings graad van hepatocyten bepaald bij 5 verschillende dieldrin behande-
ling niveaux vanaf 8 weken behandeling tot tumor ontwikkeling. Polyploidi-
sering, uitgedrukt in het percentage octaploide (8c) kernen, in onbehandelde 
CF-1 muizen werd gekenmerkt door een lineaire toename met de tijd. Dieldrin 
behandeling resulteerde in een dosis-afhankelijke toename van het percentage 
8c kernen in het begin van de behandelings periode. Na deze initiële toename 
steeg het percentage 8c kernen met dezelfde (lineaire) tijds-afhankelijkheid 
als in de controle groep. Levertumor ontwikkeling bleek te zijn verbonden 
met een constante polyploidiserings graad (ca. 21% 8c kernen) in alle be-
handel ings groepen. 
De gevonde quantitative relatie tussen polyploidisering en levertumor ont-
wikkeling riep de vraag op of een causaal verband tussen deze waarnemingen 
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bestond. Polyploidisering is een proces dat veroudering weerspiegeld; de 
toename van de polyploidisering onder invloed van dieldrin behandeling zou 
dus als een versnelling van het veroudeMngs proces opgevat kunnen worden. 
De resultaten van de isoenzym bepaling van het cytoplasmatische alanine-
amino transferase (AAT) ondersteunen deze hypothese. De expressie van het 
A-AAT isoenzym bleek in onbehandelde CF-1 muizen af te nemen bij toenemende 
leeftijd. Behandeling met dieldrin had een dosis-afhankelijke versnelling 
van dit proces tot gevolg. 
Alhoewel de oorzaak van de levertumor ontwikkeling in CF-1 muizen nog onbe-
kend is, zou de afname in de verhouding van tetraploide (4c) - diploide (2c) 
lever kernen met het ontstaan van leverkanker te maken kunnen hebben: 
a) De afname in de 4c-2c verhouding vond in alle behandelings groepen 
plaats, b) Deze afname trad, dosis-afhankelijk, eerder op bij hogere dose-
ringen, en wel zo dat het begin van dit proces ongeveer 4 maanden voor de 
gemiddelde tumor latentie tijd lag. Twee verschillende hypothesen zouden een 
verklaring kunnen geven voor een causaal verband tussen de afname in de ver-
houding van 4c-2c lever kernen en tumor ontwikkeling. 
1) Mogelijk zijn tertaploide kernen gevoeliger voor (cumulatieve) toxische 
belasting. Hierdoor zouden deze, onder invloed van dieldrin belasting, 
sneller afsterven. Om een tetraploide cel te vervangen moet een diploide 
cel zich twee maal delen . De afname in het aantal tetraploide kernen zou 
dus, bij onveranderde lever grootte en gewicht, een sterke delingsacti-
viteit bij de diploide cellen tot gevolg kunnen hebben (met daaruit 
resulterende activering van het oncogene potentiaal in de lever van 
CF-1 muizen). 
2) Een afname in de verhouding van 4c-2c lever kernen zou ook verklaard kun-
nen worden door het optreden van amitotische delingen. AanwijzJjig,en .dat 
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een dergelijk proces daadwerkelijk op kan treden in de lever van CF-1 
3 
muizen zijn verkregen met H-thymidine gemarkeerde kernen. Amitotische 
delingen kunnen genetische herverdeling tot gevolg hebben waardoor reces-
sieve kenmerken tot expressie kunnen komen. 
De hier voorgestelde hypothesen impliceren dat leverkanker zou ontstaan uit 
dioploide cellen. Uit bepalingen van de polyploidiserings graad van lever 
tumoren bleek dat deze inderdaad ontstaan waren uit een diploide cel-
populatie. 
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